1
|
Joven B, Manteca CF, Rubio E, Raya E, Pérez A, Hernández R, Manrique S, Núñez M, Díaz-Cerezo S, Moyano S, Lacetera A, García-Vicuña R. Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study. Adv Ther 2023; 40:5415-5431. [PMID: 37804475 PMCID: PMC10611868 DOI: 10.1007/s12325-023-02693-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Accepted: 09/22/2023] [Indexed: 10/09/2023]
Abstract
INTRODUCTION Given the growing interest and use of interleukin-17 inhibitors (anti-IL17) for the treatment of psoriatic arthritis (PsA), an observational study has been conducted to characterize the patient profile, treatment patterns, and persistence of ixekizumab or secukinumab in patients with PsA receiving them as first anti-IL17. METHODS This is a multicenter retrospective study, conducted at eight Spanish hospitals where data from adult patients with PsA were collected from electronic medical records. Three cohorts of patients, initiating treatment with an anti-IL17 [secukinumab 150 mg (SECU150), secukinumab 300 mg (SECU300), or ixekizumab (IXE)] between January 2019 and March 2021, were included. Demographic and clinical patient characteristics, treatment patterns, and persistence were analyzed descriptively. Continuous data were presented as mean [standard deviation (SD)] and categorical variables as frequencies with percentages. Persistence rates at 3, 6, and 12 months were calculated. RESULTS A total of 221 patients with PsA were included in the study [SECU150, 103 (46.6%); SECU300, 38 (17.2%); and IXE, 80 (36.2%)]. Treatment patterns differed by clinical characteristics: SECU150 was initiated more frequently in patients with moderate PsA and less peripheral joint involvement, while patients on SECU300 included those with a higher rate of enthesitis and active skin psoriasis, and patients on IXE showed a longer time since PsA diagnosis, more frequent comorbidities, joint involvement, and diagnosed skin psoriasis. Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) were previously administered in 88.2% of patients and biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) were administered in 72.9%. The mean number of previous b/tsDMARDs was 2.4 (SD 1.5) in the IXE cohort, 1.7 (SD 0.9) in the SECU300 cohort, and 1.6 (SD 1.0) for those in the SECU150 cohort. The global persistence on all anti-IL17 was 97.2%, 88.4%, and 81.0% at 3, 6, and 12 months, respectively. The most frequent reason for discontinuation across the three cohorts was lack of effectiveness (16.7%; 37/221). CONCLUSIONS Most of the patients with PsA treated with anti-IL17 in Spain had moderate to severe disease activity, high peripheral joint and skin involvement, and had received previous b/tsDMARDs. More than 80% of patients with a 1-year follow-up persisted on anti-IL17, with the highest rate observed in the IXE cohort, followed by the SECU150 then SECU300 cohorts.
Collapse
Affiliation(s)
- Beatriz Joven
- Rheumatology Department, Hospital 12 de Octubre, Madrid, Spain
| | | | - Esteban Rubio
- Rheumatology Department, Hospital Virgen del Rocío, Seville, Spain
| | - Enrique Raya
- Rheumatology Department, Hospital Universitario Clínico San Cecilio de Granada, Granada, Spain
| | - Alba Pérez
- Rheumatology and Traumatology Department Hospital Puerta del Mar, Cádiz, Spain
| | - Raquel Hernández
- Rheumatology Department, Hospital Universitario de Valme, Seville, Spain
| | - Sara Manrique
- Rheumatology Department, Hospital Carlos Haya, Málaga, Spain
| | - Mercedes Núñez
- Medical Department, Eli Lilly and Company, Av. de la Industria, 30, Alcobendas, 28108, Madrid, Spain
| | - Silvia Díaz-Cerezo
- Medical Department, Eli Lilly and Company, Av. de la Industria, 30, Alcobendas, 28108, Madrid, Spain.
| | - Sebastián Moyano
- Medical Department, Eli Lilly and Company, Av. de la Industria, 30, Alcobendas, 28108, Madrid, Spain
| | | | | |
Collapse
|
2
|
Joven B, Hernández Sánchez R, Pérez-Pampín E, Aragón Díez Á, Almodóvar R, Martínez-Ferrer Á, Belzunegui J, Rubio E, Díaz-Cerezo S, Moyano S, Gómez-Barrera M, Yébenes M, Núñez M. Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study. Rheumatol Ther 2023; 10:1319-1333. [PMID: 37481752 PMCID: PMC10468471 DOI: 10.1007/s40744-023-00584-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Accepted: 06/30/2023] [Indexed: 07/25/2023] Open
Abstract
INTRODUCTION Ixekizumab (IXE) is an IgG4-type monoclonal antibody targeting IL-17A indicated alone or in combination with methotrexate, for the treatment of active psoriatic arthritis (PsA) in adult patients with insufficient response or with intolerance to one or more disease-modifying anti-rheumatic drug (DMARD) therapy. The PRO-STIP study aimed to describe persistence, patient characteristics, treatment patterns, and effectiveness in patients with PsA receiving IXE in a real-world clinical setting in Spain. METHODS This was an observational, multicentric, retrospective, longitudinal study in adult PsA patients who started IXE between January 2019 and December 2020, with at least 24 weeks of follow-up. A descriptive analysis of patient characteristics and treatment patterns was performed. The primary objective, treatment persistence, was estimated by Kaplan-Meier survival curve. Effectiveness was evaluated by Disease Activity in Psoriatic Arthritis (DAPSA) scores at baseline and at 12 and 24 weeks. RESULTS Eighty-nine patients met the selection criteria (55.1% women and mean age 51.5 years). The median time from PsA diagnosis to starting IXE was 7.7 years (IQR 3.4-14.6). Prior to IXE, 95.5% patients had been treated with at least one biologic or targeted synthetic DMARD (b/tsDMARD). The observed persistence rates were 95.5%, 84.3% and 68.5% at 24, 48, and 104 weeks, respectively. The median persistence was not reached in the study period (mean persistence, 86.9 [95% CI 80.6-93.2] weeks). Twenty-eight (31.5%) patients discontinued IXE, 19 patients (21.3%) due to loss of effectiveness and two patients (2.2%) due to adverse events. In patients receiving treatment and with available effectiveness assessment (n = 24), DAPSA decreased significantly from baseline 23.7 (95% CI 19.5-27.9) to 14.8 (95% CI 10.5-19.2) at 12 weeks (p = 0.005) and 14.3 (95% CI 11.1-17.4) at 24 weeks (p = 0.004). CONCLUSIONS PsA patients treated with IXE in a real-world setting show high treatment persistence through 104 weeks and improvements in disease activity after treatment initiation. This suggests that IXE could be an effective treatment for patients with PsA. RETROSPECTIVELY REGISTERED Date of registration: 25th May 2021.
Collapse
Affiliation(s)
- Beatriz Joven
- Hospital Universitario, 12 de Octubre, Madrid, Spain
| | | | - Eva Pérez-Pampín
- Hospital Clínico Universitario Santiago, Santiago de Compostela, Spain
| | | | | | | | | | - Esteban Rubio
- Hospital Universitario Virgen del Rocío, Seville, Spain
| | | | | | - Manuel Gómez-Barrera
- Pharmacoeconomics and Outcomes Research Iberia (PORIB), Pozuelo de Alarcón, Madrid, Spain
| | - María Yébenes
- Pharmacoeconomics and Outcomes Research Iberia (PORIB), Pozuelo de Alarcón, Madrid, Spain
| | | |
Collapse
|
3
|
Batista-Liz JC, Calvo-Río V, Sebastián Mora-Gil M, Sevilla-Pérez B, Márquez A, Leonardo MT, Peñalba A, Carmona FD, Narvaez J, Martín-Penagos L, Belmar-Vega L, Gómez-Fernández C, Caminal-Montero L, Collado P, Quiroga-Colina P, Uriarte-Ecenarro M, Rubio E, Luque ML, Blanco-Madrigal JM, Galíndez-Agirregoikoa E, Martín J, Castañeda S, González-Gay MA, Blanco R, Pulito-Cueto V, López-Mejías R. Mucosal Immune Defence Gene Polymorphisms as Relevant Players in the Pathogenesis of IgA Vasculitis? Int J Mol Sci 2023; 24:13063. [PMID: 37685869 PMCID: PMC10488110 DOI: 10.3390/ijms241713063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Revised: 08/17/2023] [Accepted: 08/18/2023] [Indexed: 09/10/2023] Open
Abstract
ITGAM-ITGAX (rs11150612, rs11574637), VAV3 rs17019602, CARD9 rs4077515, DEFA (rs2738048, rs10086568), and HORMAD2 rs2412971 are mucosal immune defence polymorphisms, that have an impact on IgA production, described as risk loci for IgA nephropathy (IgAN). Since IgAN and Immunoglobulin-A vasculitis (IgAV) share molecular mechanisms, with the aberrant deposit of IgA1 being the main pathophysiologic feature of both entities, we assessed the potential influence of the seven abovementioned polymorphisms on IgAV pathogenesis. These seven variants were genotyped in 381 Caucasian IgAV patients and 997 matched healthy controls. No statistically significant differences were observed in the genotype and allele frequencies of these seven polymorphisms when the whole cohort of IgAV patients and those with nephritis were compared to controls. Similar genotype and allele frequencies of all polymorphisms were disclosed when IgAV patients were stratified according to the age at disease onset or the presence/absence of gastrointestinal or renal manifestations. Likewise, no ITGAM-ITGAX and DEFA haplotype differences were observed when the whole cohort of IgAV patients, along with those with nephritis and controls, as well as IgAV patients, stratified according to the abovementioned clinical characteristics, were compared. Our results suggest that mucosal immune defence polymorphisms do not represent novel genetic risk factors for IgAV pathogenesis.
Collapse
Affiliation(s)
- Joao Carlos Batista-Liz
- Immunopathology Group, Rheumatology Department, Hospital Universitario Marqués de Valdecilla-IDIVAL, 39011 Santander, Spain; (J.C.B.-L.); (V.C.-R.); (M.S.M.-G.); (R.B.)
| | - Vanesa Calvo-Río
- Immunopathology Group, Rheumatology Department, Hospital Universitario Marqués de Valdecilla-IDIVAL, 39011 Santander, Spain; (J.C.B.-L.); (V.C.-R.); (M.S.M.-G.); (R.B.)
| | - María Sebastián Mora-Gil
- Immunopathology Group, Rheumatology Department, Hospital Universitario Marqués de Valdecilla-IDIVAL, 39011 Santander, Spain; (J.C.B.-L.); (V.C.-R.); (M.S.M.-G.); (R.B.)
| | - Belén Sevilla-Pérez
- Division of Paediatrics, Hospital Universitario San Cecilio, 18016 Granada, Spain;
| | - Ana Márquez
- Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, 18016 Granada, Spain; (A.M.); (J.M.)
| | - María Teresa Leonardo
- Division of Paediatrics, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain; (M.T.L.); (A.P.)
| | - Ana Peñalba
- Division of Paediatrics, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain; (M.T.L.); (A.P.)
| | - Francisco David Carmona
- Departamento de Genética e Instituto de Biotecnología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, 18071 Granada, Spain;
- Instituto de Investigación Biosanitaria ibs. Granada, 18012 Granada, Spain
| | - Javier Narvaez
- Division of Rheumatology, Hospital Universitario de Bellvitge, 08907 Barcelona, Spain;
| | - Luis Martín-Penagos
- Immunopathology Group, Division of Nephrology, Hospital Universitario Marqués de Valdecilla-IDIVAL, 39011 Santander, Spain; (L.M.-P.); (L.B.-V.)
| | - Lara Belmar-Vega
- Immunopathology Group, Division of Nephrology, Hospital Universitario Marqués de Valdecilla-IDIVAL, 39011 Santander, Spain; (L.M.-P.); (L.B.-V.)
| | | | - Luis Caminal-Montero
- Internal Medicine Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain;
| | - Paz Collado
- Division of Rheumatology, Hospital Universitario Severo Ochoa, 28911 Madrid, Spain;
| | - Patricia Quiroga-Colina
- Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, 28006 Madrid, Spain; (P.Q.-C.); (M.U.-E.); (S.C.)
| | - Miren Uriarte-Ecenarro
- Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, 28006 Madrid, Spain; (P.Q.-C.); (M.U.-E.); (S.C.)
| | - Esteban Rubio
- Department of Rheumatology, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain; (E.R.); (M.L.L.)
| | - Manuel León Luque
- Department of Rheumatology, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain; (E.R.); (M.L.L.)
| | - Juan María Blanco-Madrigal
- Division of Rheumatology, Hospital Universitario de Basurto, 48013 Bilbao, Spain; (J.M.B.-M.); (E.G.-A.)
| | - Eva Galíndez-Agirregoikoa
- Division of Rheumatology, Hospital Universitario de Basurto, 48013 Bilbao, Spain; (J.M.B.-M.); (E.G.-A.)
| | - Javier Martín
- Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, 18016 Granada, Spain; (A.M.); (J.M.)
| | - Santos Castañeda
- Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, 28006 Madrid, Spain; (P.Q.-C.); (M.U.-E.); (S.C.)
| | - Miguel Angel González-Gay
- Department of Rheumatology, IIS-Fundación Jiménez Díaz, 28040 Madrid, Spain;
- School of Medicine, Universidad de Cantabria, 39011 Santander, Spain
| | - Ricardo Blanco
- Immunopathology Group, Rheumatology Department, Hospital Universitario Marqués de Valdecilla-IDIVAL, 39011 Santander, Spain; (J.C.B.-L.); (V.C.-R.); (M.S.M.-G.); (R.B.)
| | - Verónica Pulito-Cueto
- Immunopathology Group, Rheumatology Department, Hospital Universitario Marqués de Valdecilla-IDIVAL, 39011 Santander, Spain; (J.C.B.-L.); (V.C.-R.); (M.S.M.-G.); (R.B.)
| | - Raquel López-Mejías
- Immunopathology Group, Rheumatology Department, Hospital Universitario Marqués de Valdecilla-IDIVAL, 39011 Santander, Spain; (J.C.B.-L.); (V.C.-R.); (M.S.M.-G.); (R.B.)
| |
Collapse
|
4
|
Herrera S, Torralbo B, Herranz S, Bernal-Maurandi J, Rubio E, Pitart C, Fortes I, Valls S, Rodríguez L, Santana G, Bodro M, Garcia-Vidal C, Hernández-Meneses M, Puerta P, Morata L, Villella A, Bertran MJ, Brey M, Soriano A, Del Río A, Martinez JA. Carriage of multidrug-resistant Gram-negative bacilli: duration and risk factors. Eur J Clin Microbiol Infect Dis 2023; 42:631-638. [PMID: 36964885 DOI: 10.1007/s10096-023-04581-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2022] [Accepted: 02/24/2023] [Indexed: 03/26/2023]
Abstract
Identification of risk factors influencing the duration of carriage of multidrug-resistant Gram-negative bacilli (MDR-GNB) may be useful for infection control. The aim of this study is to estimate the impact of several factors collected for routine hospital surveillance on the duration of carriage of selected MDR-GNB. From January 2015 to July 2021, patients with at least two clinical/surveillance samples positive for MDR-GNB different from ESBL-producing E. coli or AmpC - exclusively producing Enterobacterales were assessed. Microorganisms, age, number of admissions, clinical or rectal sample, sex, and admission service were evaluated as risk factors. Multivariate analysis was performed by a Cox proportional hazard model. A total of 1981 episodes of colonization were included. Involved microorganisms were ESBL-Klebsiella pneumoniae (KP) in 1057 cases (53.4%), other ESBL-non-E. coli Enterobacterales in 91 (4.6%), OXA-48-KP in 263 (13.3%), KPC-KP in 90 (4.5%), VIM-KP in 29 (1.5%), carbapenemase-producing non-KP Enterobacterales (CP-non-KP) in 124 (6.3%), and MDR Pseudomonas aeruginosa (MDR-PAER) in 327 (16.5%). No differences in duration of colonization were observed among ESBL-KP (median colonization time 320 days), ESBL-non-E. coli Enterobacterales (226 days), OXA48-KP (305 days), and MDR-PAER (321 days). For each group, duration of colonization was significantly longer than that of KPC-KP (median colonization time 60 days), VIM-KP (138 days), and CP-non-KP (71 days). Male sex (HR = 0.88; 95% CI 0.78-0.99), detection in Hepatology-Gastroenterology (HR = 0.71; 95% CI 0.54-0.93), clinical sample (HR = 0.61; 95% CI 0.53-0.69), and > 2 admissions after first detection (HR = 0.47; 95% CI 0.42-0.52) were independent predictors of longer carriage, whereas VIM-KP (HR = 1.61; 95% CI 1.04-2.48), KPC-KP (HR = 1.85; 95% CI 1.49-2.3), and CP-non-KP (HR = 1.92; 95% CI 1.49-2.47) were associated with shorter colonization time. Duration of colonization was significantly longer for ESBL-KP, other ESBL-non-E. coli Enterobacterales, OXA-48-KP, and MDR-PAER. For these microorganisms, prolonging surveillance up to 2.5-3 years should be considered. Male sex, clinical sample, multiple readmissions, admission service, and type of microorganism are independent predictors of the duration of carriage.
Collapse
Affiliation(s)
- S Herrera
- Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, C. de Villarroel, 170, 08036, Barcelona, Spain
| | - B Torralbo
- Preventive Medicine, Hospital Clinic of Barcelona-IDIBAPS, Barcelona, Spain
| | - S Herranz
- Preventive Medicine, Hospital Clinic of Barcelona-IDIBAPS, Barcelona, Spain
| | - J Bernal-Maurandi
- Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, C. de Villarroel, 170, 08036, Barcelona, Spain
| | - E Rubio
- Department of Microbiology, Hospital Clinic, University of Barcelona, ISGLOBAL, Barcelona, Spain
| | - C Pitart
- Department of Microbiology, Hospital Clinic, University of Barcelona, ISGLOBAL, Barcelona, Spain
| | - I Fortes
- Preventive Medicine, Hospital Clinic of Barcelona-IDIBAPS, Barcelona, Spain
| | - S Valls
- Preventive Medicine, Hospital Clinic of Barcelona-IDIBAPS, Barcelona, Spain
| | - L Rodríguez
- Preventive Medicine, Hospital Clinic of Barcelona-IDIBAPS, Barcelona, Spain
| | - G Santana
- Preventive Medicine, Hospital Clinic of Barcelona-IDIBAPS, Barcelona, Spain
| | - M Bodro
- Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, C. de Villarroel, 170, 08036, Barcelona, Spain
| | - C Garcia-Vidal
- Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, C. de Villarroel, 170, 08036, Barcelona, Spain
| | - M Hernández-Meneses
- Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, C. de Villarroel, 170, 08036, Barcelona, Spain
| | - P Puerta
- Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, C. de Villarroel, 170, 08036, Barcelona, Spain
| | - L Morata
- Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, C. de Villarroel, 170, 08036, Barcelona, Spain
| | - A Villella
- Preventive Medicine, Hospital Clinic of Barcelona-IDIBAPS, Barcelona, Spain
| | - M J Bertran
- Preventive Medicine, Hospital Clinic of Barcelona-IDIBAPS, Barcelona, Spain
| | - M Brey
- Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, C. de Villarroel, 170, 08036, Barcelona, Spain
| | - A Soriano
- Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, C. de Villarroel, 170, 08036, Barcelona, Spain
| | - A Del Río
- Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, C. de Villarroel, 170, 08036, Barcelona, Spain
| | - J A Martinez
- Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, C. de Villarroel, 170, 08036, Barcelona, Spain.
| |
Collapse
|
5
|
García-González J, García-de-la-Mària C, Cañas M, Rubio E, Hernández-Meneses M, Ambrosioni J, Vidal B, Sandoval E, Moreno A, Miró J. Actividad in vitro de Ampicilina más Ceftriaxona Frente a e. Gallynarum, e. Durans y e. Casseliflavus Aislados en Pacientes con Endocarditis. Cirugía Cardiovascular 2022. [DOI: 10.1016/j.circv.2022.03.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
6
|
Quijada L, Baral H, Johnston P, Pärtel K, Mitchell J, Hosoya T, Madrid H, Kosonen T, Helleman S, Rubio E, Stöckli E, Huhtinen S, Pfister D. A review of Hyphodiscaceae. Stud Mycol 2022. [DOI: 10.3114/sim.2022.103.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
In a recently published classification scheme for Leotiomycetes, the new family Hyphodiscaceae was erected; unfortunately, this study was rife with phylogenetic misinterpretations and hampered by a poor understanding of this group of fungi. This manifested in the form of an undiagnostic familial description, an erroneous familial circumscription, and the redescription of the type species of an included genus as a new species in a different genus. The present work corrects these errors by incorporating new molecular data from this group into phylogenetic analyses and examining the morphological features of the included taxa. An emended description of Hyphodiscaceae is provided, notes and descriptions of the included genera are supplied, and keys to genera and species in Hyphodiscaceae are supplied. Microscypha cajaniensis is combined in Hyphodiscus, and Scolecolachnum nigricans is a taxonomic synonym of Fuscolachnum pteridis. Future work in this family should focus on increasing phylogenetic sampling outside of Eurasia and better characterising described species to help resolve outstanding issues.
Collapse
Affiliation(s)
- L. Quijada
- Farlow Herbarium and Library of Cryptogamic Botany, Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts 02138, USA
| | | | - P.R. Johnston
- Manaaki Whenua Landcare Research, Private Bag 92170, Auckland 1072, New Zealand
| | - K. Pärtel
- Institute of Ecology and Earth Sciences, University of Tartu, J. Liivi St. 2, 50409, Tartu, Estonia
- Mycological Collections, Institute of Agriculture and Environmental Sciences, Estonian University of Life Sciences, Kreutzwaldi St. 5, 51006, Tartu, Estonia
| | - J.K. Mitchell
- Farlow Herbarium and Library of Cryptogamic Botany, Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts 02138, USA
| | - T. Hosoya
- Department of Botany, National Museum of Nature and Science, 4-1-1 Amakubo, Tsukuba, Ibaraki 305-0005, Japan
| | - H. Madrid
- Departamento de Tecnología Médica, Facultad de Ciencias de la Salud, Universidad de Tarapacá, Sede Iquique, Av. Luis Emilio Recabarren 2477, Iquique, Chile
| | - T. Kosonen
- Department of Botany, Swedish Museum of Natural History, P.O. Box 50007, SE-104 05 Stockholm, Sweden
- Herbarium, Biodiversity Unit, University of Turku, FI-20014 Turku, Finland
| | | | - E. Rubio
- José Cueto 3, 5º B Avilés, Asturias
| | - E. Stöckli
- Haut du Village, 42345 La Chaux-des-Breuleux, Switzerland
| | - S. Huhtinen
- Herbarium, Biodiversity Unit, University of Turku, FI-20014 Turku, Finland
| | - D.H. Pfister
- Farlow Herbarium and Library of Cryptogamic Botany, Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts 02138, USA
| |
Collapse
|
7
|
Tornero-Molina J, Alperi-López M, Castellví I, de Agustín-de Oro JJ, Escudero A, García-Vicuña R, González-Gay MÁ, Hidalgo C, Rubio E, Sanmartí R, Casamira N, Calvo-Alén J. Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis. Reumatol Clin (Engl Ed) 2022; 18:33-41. [PMID: 35090610 DOI: 10.1016/j.reumae.2020.08.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Accepted: 08/20/2020] [Indexed: 06/14/2023]
Abstract
OBJECTIVE We aimed to develop recommendations for the management of methotrexate (MTX) when considering the combination with biological (b) or targeted synthetic (ts) disease modifying drugs (DMARDs) in rheumatoid arthritis (RA). METHODS Eleven experts on RA were selected. Two coordinators formulated 13 questions about the combination therapy of MTX with bDMARDs or tsDMARDs. A systematic review was conducted to answer the questions. Inclusion and exclusion criteria were established as well as the search strategies (Medline, Embase and the Cochrane Library were searched up to January 2019). Two reviewers selected the articles and collected data. Simultaneously, EULAR and ACR meeting abstracts were evaluated. Based on this evidence, the coordinators proposed preliminary recommendations that the experts discussed and voted in a nominal group meeting. The level of evidence and grade of recommendation was established using the Oxford Center for Evidence Based Medicine and the level of agreement with a Delphi. Agreement was established if at least 80% of the experts voted 'yes' (yes/no). RESULTS The systematic review retrieved 513 citations of which 61 were finally included. A total of 10 recommendations were generated, voted and accepted. The level of agreement was very high in all of them and it was achieved in the first Delphi round. Final recommendations cover aspects such as the optimal MTX dosage, tapering strategy or patients' risk management. CONCLUSIONS This document is intended to help clinicians solve usual clinical questions and facilitate decision making when treating RA patients with MTX in combination with bDMARDs or tsDMARDs.
Collapse
Affiliation(s)
| | | | - Ivan Castellví
- Servicio de Reumatología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | | | - Alejandro Escudero
- Servicio de Reumatología, Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain
| | | | | | - Cristina Hidalgo
- Servicio de Reumatología, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
| | - Esteban Rubio
- Servicio de Reumatología, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - Raimon Sanmartí
- Servicio de Reumatología, Hospital Universitari Clínic, Barcelona, Spain
| | - Núria Casamira
- Departamento Médico, Laboratorios Gebro Pharma, Barcelona, Spain
| | - Jaime Calvo-Alén
- Servicio de Reumatología, Hospital Universitario Araba, Vitoria-Gasteiz, Spain
| |
Collapse
|
8
|
Gijón-Conde T, Rubio E, Gorostidi M, Vinyoles E, Armario P, Rodilla E, Segura J, Divisón-Garrote JA, García-Donaire JA, Molinero A, Ruilope LM. 2021 Spanish Society of Hypertension position statement about telemedicine. Hipertens Riesgo Vasc 2021; 38:186-196. [PMID: 33888438 PMCID: PMC8054212 DOI: 10.1016/j.hipert.2021.03.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Accepted: 03/29/2021] [Indexed: 12/01/2022]
Abstract
The pandemic caused by coronavirus SARS-CoV-2 (COVID-19) has forced, in many cases, to replace face-to-face consultation with the telematic consultation, in order to reduce the risk of contagion associated with the presence of patients in health centres. This change may represent an opportunity for a different and more effective communication between professionals and patients, allowing better accessibility to medical care and more systematic and comprehensive approach to patients with hypertension and cardiovascular risk. However, organisational tools are needed to facilitate communication between patients and professionals, specifically with the exchange of clinical data by remote monitoring of variables associated with hypertension and cardiovascular risk (blood pressure, weight, height, blood tests…), and allow monitoring of adherence to treatments, lifestyles and risk factors. It would be desirable for this to be carried out by multidisciplinary teams, both from primary care, hospital and community pharmacy, with an adequate coordination of care. This document of the Spanish Society of Hypertension (SEH-LELHA) tries to give the keys to improve the quality of care of telematic consultations of patients with hypertension and cardiovascular risk, provide basic criteria of telematic or face to face attention and systematise their content. Likewise, the follow-up criteria are proposed by the different professionals.
Collapse
Affiliation(s)
- T Gijón-Conde
- Centro de Salud Cerro del Aire, Departamento de Medicina, Universidad Autónoma Madrid/IdiPAZ y CIBERESP, Majadahonda, Madrid, Spain.
| | - E Rubio
- Servicio de Nefrología, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain.
| | - M Gorostidi
- Servicio de Nefrología, Hospital Universitario Central de Asturias, RedinRen, Universidad de Oviedo, Oviedo, Spain
| | - E Vinyoles
- Centre d'Atenció Primària La Mina, Departamento de Medicina, Universidad de Barcelona, Barcelona, Spain
| | - P Armario
- Área Atención Integrada de Riesgo Vascular, Departamento de Medicina Interna, Hospital Moisès Broggi Sant Joan Despi, Universidad de Barcelona, Sant Joan Despí, Barcelona, Spain
| | - E Rodilla
- Servicio de Medicina Interna, Hospital Universitario de Sagunto, Universidad Cardenal Herrera-CEU, Sagunto, Valencia, Spain
| | - J Segura
- Instituto de Investigación i+12, Hospital Universitario 12 de Octubre, Madrid, Spain; Unidad de Hipertensión, Servicio de Nefrología, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - J A Divisón-Garrote
- Centro de Salud de Casas Ibáñez, Universidad Católica San Antonio, Casas Ibáñez, Albacete, Spain
| | | | - A Molinero
- Sociedad Española de Farmacia Comunitaria (SEFAC), Spain
| | - L M Ruilope
- Instituto de Investigación i+12, Hospital Universitario 12 de Octubre, Madrid, Spain; Unidad de Hipertensión, Servicio de Nefrología, Hospital Universitario 12 de Octubre, Madrid, Spain; Escuela de Estudios de Doctorado e Investigación, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, Spain
| |
Collapse
|
9
|
Prieto-Peña D, Remuzgo-Martínez S, Genre F, Pulito-Cueto V, Atienza-Mateo B, Llorca J, Sevilla-Pérez B, Ortego-Centeno N, Marquez A, Lera-Gómez L, Leonardo MT, Peñalba A, Narváez J, Martín-Penagos L, Rodrigo E, Miranda-Filloy JA, Caminal-Montero L, Collado P, Sánchez Pérez J, de Argila D, Rubio E, León Luque M, Blanco-Madrigal JM, Galíndez-Agirregoikoa E, Gualillo O, Martín J, Castañeda S, Blanco R, González-Gay MA, López-Mejías R. Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis. Sci Rep 2021; 11:16163. [PMID: 34373564 PMCID: PMC8352942 DOI: 10.1038/s41598-021-95762-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Accepted: 07/30/2021] [Indexed: 12/27/2022] Open
Abstract
Cytokines signalling pathway genes are crucial factors of the genetic network underlying the pathogenesis of Immunoglobulin-A vasculitis (IgAV), an inflammatory vascular condition. An influence of the interleukin (IL)33- IL1 receptor like (IL1RL)1 signalling pathway on the increased risk of several immune-mediated diseases has been described. Accordingly, we assessed whether the IL33-IL1RL1 pathway represents a novel genetic risk factor for IgAV. Three tag polymorphisms within IL33 (rs3939286, rs7025417 and rs7044343) and three within IL1RL1 (rs2310173, rs13015714 and rs2058660), that also were previously associated with several inflammatory diseases, were genotyped in 380 Caucasian IgAV patients and 845 matched healthy controls. No genotypes or alleles differences were observed between IgAV patients and controls when IL33 and IL1RL1 variants were analysed independently. Likewise, no statistically significant differences were found in IL33 or IL1RL1 genotype and allele frequencies when IgAV patients were stratified according to the age at disease onset or to the presence/absence of gastrointestinal (GI) or renal manifestations. Similar results were disclosed when IL33 and IL1RL1 haplotypes were compared between IgAV patients and controls and between IgAV patients stratified according to the clinical characteristics mentioned above. Our results suggest that the IL33-IL1RL1 signalling pathway does not contribute to the genetic network underlying IgAV.
Collapse
Affiliation(s)
- Diana Prieto-Peña
- Research Group On Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain
| | - Sara Remuzgo-Martínez
- Research Group On Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain
| | - Fernanda Genre
- Research Group On Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain
| | - Verónica Pulito-Cueto
- Research Group On Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain
| | - Belén Atienza-Mateo
- Research Group On Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain.,López Albo´ Post-Residency Programme, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Javier Llorca
- Epidemiology and Computational Biology Department, School of Medicine, Universidad de Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain
| | | | | | - Ana Marquez
- Instituto de Parasitología y Biomedicina 'López-Neyra', CSIC, PTS Granada, Granada, Spain.,Systemic Autoimmune Disease Unit, Hospital Universitario Clínico San Cecilio, Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain
| | - Leticia Lera-Gómez
- Research Group On Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain
| | - María Teresa Leonardo
- Division of Paediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Ana Peñalba
- Division of Paediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Javier Narváez
- Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
| | - Luis Martín-Penagos
- Division of Nephrology, Hospital Universitario Marqués de Valdecilla, IDIVAL-REDINREN, Santander, Spain
| | - Emilio Rodrigo
- Division of Nephrology, Hospital Universitario Marqués de Valdecilla, IDIVAL-REDINREN, Santander, Spain
| | | | - Luis Caminal-Montero
- Division of Rheumatology, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
| | - Paz Collado
- Division of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain
| | | | - Diego de Argila
- Department of Dermatology, Hospital Universitario de La Princesa, Madrid, Spain
| | - Esteban Rubio
- Department of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - Manuel León Luque
- Department of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | | | | | - Oreste Gualillo
- SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
| | - Javier Martín
- Instituto de Parasitología y Biomedicina 'López-Neyra', CSIC, PTS Granada, Granada, Spain
| | - Santos Castañeda
- Department of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain
| | - Ricardo Blanco
- Research Group On Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain
| | - Miguel A González-Gay
- Research Group On Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain.,School of Medicine, Universidad de Cantabria, Santander, Spain.,Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Raquel López-Mejías
- Research Group On Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain.
| |
Collapse
|
10
|
Prieto-Peña D, Bernabeu P, Vela P, Narváez J, Fernández-López JC, Freire-González M, González-Álvarez B, Solans-Laqué R, Callejas Rubio JL, Ortego N, Fernández-Díaz C, Rubio E, García-Morillo S, Minguez M, Fernández-Carballido C, de Miguel E, Melchor S, Salgado E, Bravo B, Romero-Yuste S, Salvatierra J, Hidalgo C, Manrique S, Romero-Gómez C, Moya P, Álvarez-Rivas N, Mendizabal J, Ortiz-Sanjuán F, Pérez de Pedro I, Alonso-Valdivielso JL, Perez-Sanchez L, Roldán R, Fernandez-Llanio N, Gómez de la Torre R, Suarez S, Montesa Cabrera MJ, Delgado Sánchez M, Loricera J, Atienza-Mateo B, Castañeda S, González-Gay MA, Blanco R. Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review. Ther Adv Musculoskelet Dis 2021; 13:1759720X211020917. [PMID: 34211589 PMCID: PMC8216399 DOI: 10.1177/1759720x211020917] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2021] [Accepted: 05/10/2021] [Indexed: 12/27/2022] Open
Abstract
Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu’s arteritis (TAK) in clinical practice. Methods: A multicenter study of Caucasian patients with refractory TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events. A comparative study between patients who received TCZ as monotherapy (TCZMONO) and combined with conventional disease modifying anti-rheumatic drugs (cDMARDs) (TCZCOMBO) was performed. Results: The study comprised 54 patients (46 women/8 men) with a median [interquartile range (IQR)] age of 42.0 (32.5–50.5) years. TCZ was started after a median (IQR) of 12.0 (3.0–31.5) months since TAK diagnosis. Remission was achieved in 12/54 (22.2%), 19/49 (38.8%), 23/44 (52.3%), and 27/36 (75%) patients at 1, 3, 6, and 12 months, respectively. The prednisone dose was reduced from 30.0 mg/day (12.5–50.0) to 5.0 (0.0–5.6) mg/day at 12 months. An improvement in imaging findings was reported in 28 (73.7%) patients after a median (IQR) of 9.0 (6.0–14.0) months. Twenty-three (42.6%) patients were on TCZMONO and 31 (57.4%) on TCZCOMBO: MTX (n = 28), cyclosporine A (n = 2), azathioprine (n = 1). Patients on TCZCOMBO were younger [38.0 (27.0–46.0) versus 45.0 (38.0–57.0)] years; difference (diff) [95% confidence interval (CI) = -7.0 (-17.9, -0.56] with a trend to longer TAK duration [21.0 (6.0–38.0) versus 6.0 (1.0–23.0)] months; diff 95% CI = 15 (-8.9, 35.5), and higher c-reactive protein [2.4 (0.7–5.6) versus 1.3 (0.3–3.3)] mg/dl; diff 95% CI = 1.1 (-0.26, 2.99). Despite these differences, similar outcomes were observed in both groups (log rank p = 0.862). Relevant adverse events were reported in six (11.1%) patients, but only three developed severe events that required TCZ withdrawal. Conclusion: TCZ in monotherapy, or combined with cDMARDs, is effective and safe in patients with refractory TAK of Caucasian origin.
Collapse
Affiliation(s)
- Diana Prieto-Peña
- Department of Rheumatology, Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Pilar Bernabeu
- Department of Rheumatology, Hospital General de Alicante, Alicante, Spain
| | - Paloma Vela
- Department of Rheumatology, Hospital General de Alicante, Alicante, Spain
| | - Javier Narváez
- Department of Rheumatology, Hospital de Bellvitge, Barcelona, Spain
| | | | | | | | - Roser Solans-Laqué
- Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain
| | | | - Norberto Ortego
- Autoimmune Disease Unit, Hospital San Cecilio, Granada, Spain
| | - Carlos Fernández-Díaz
- Department of Rheumatology, H. Universitario de La Princesa, IIS-Princesa, Madrid, Spain
| | - Esteban Rubio
- Autoimmune Disease Unit, Hospital Virgen del Rocío, Sevilla, Spain
| | | | - Mauricio Minguez
- Department of Rheumatology, Hospital San Juan de Alicante, Alicante, Spain
| | | | - Eugenio de Miguel
- Department of Rheumatology, Hospital Universitario La Paz, Madrid, Spain
| | - Sheila Melchor
- Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Eva Salgado
- Department of Rheumatology, Complejo H. Universitario de Ourense, Ourense, Spain
| | - Beatriz Bravo
- Department of Rheumatology, Hospital Virgen de las Nieves, Granada, Spain
| | - Susana Romero-Yuste
- Department of Rheumatology, Complejo H. Universitario de Pontevedra, Pontevedra, Spain
| | | | - Cristina Hidalgo
- Department of Rheumatology, Complejo Universitario de Salamanca, Salamanca, Spain
| | - Sara Manrique
- Autoimmune Disease Unit, Hospital Regional de Málaga, Málaga, Spain
| | | | - Patricia Moya
- Department of Rheumatology, Hospital Sant Pau, Barcelona, Spain
| | | | - Javier Mendizabal
- Department of Rheumatology, Complejo Hospitalario de Navarra, Pamplona, Spain
| | | | | | | | - Laura Perez-Sanchez
- Department of Rheumatology, Hospital Universitario Reina Sofía, Córdoba, Spain
| | - Rosa Roldán
- Department of Rheumatology, Hospital Universitario Reina Sofía, Córdoba, Spain
| | | | | | - Silvia Suarez
- Autoimmune Disease Unit, Hospital Universitario Central de Asturias, Oviedo, Spain
| | | | | | - Javier Loricera
- Department of Rheumatology, Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Belén Atienza-Mateo
- Department of Rheumatology, Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Santos Castañeda
- Department of Rheumatology, H. Universitario de La Princesa, IIS-Princesa, Madrid, Spain
| | - Miguel A González-Gay
- Rheumatology Division, Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Avenida Valdecilla s/n, Santander, 39008, Spain
| | - Ricardo Blanco
- Department of Rheumatology, Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| |
Collapse
|
11
|
Prieto-Peña D, Genre F, Remuzgo-Martínez S, Pulito-Cueto V, Atienza-Mateo B, Llorca J, Sevilla-Pérez B, Ortego-Centeno N, Lera-Gómez L, Leonardo MT, Peñalba A, Narváez J, Martín-Penagos L, Rodrigo E, Miranda-Filloy JA, Caminal-Montero L, Collado P, Pérez JS, de Argila D, Rubio E, Luque ML, Blanco-Madrigal JM, Galíndez-Agirregoikoa E, Gualillo O, Martín J, Castañeda S, Blanco R, González-Gay MA, López-Mejías R. BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis. Sci Rep 2021; 11:11510. [PMID: 34075170 PMCID: PMC8169776 DOI: 10.1038/s41598-021-91055-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Accepted: 05/21/2021] [Indexed: 12/15/2022] Open
Abstract
BAFF, APRIL and BAFF-R are key proteins involved in the development of B-lymphocytes and autoimmunity. Additionally, BAFF, APRIL and BAFFR polymorphisms were associated with immune-mediated conditions, being BAFF GCTGT>A a shared insertion-deletion genetic variant for several autoimmune diseases. Accordingly, we assessed whether BAFF, APRIL and BAFFR represent novel genetic risk factors for Immunoglobulin-A vasculitis (IgAV), a predominantly B-lymphocyte inflammatory condition. BAFF rs374039502, which colocalizes with BAFF GCTGT>A, and two tag variants within APRIL (rs11552708 and rs6608) and BAFFR (rs7290134 and rs77874543) were genotyped in 386 Caucasian IgAV patients and 806 matched healthy controls. No genotypes or alleles differences were observed between IgAV patients and controls when BAFF, APRIL and BAFFR variants were analysed independently. Likewise, no statistically significant differences were found in the genotype and allele frequencies of BAFF, APRIL or BAFFR when IgAV patients were stratified according to the age at disease onset or to the presence/absence of gastrointestinal (GI) or renal manifestations. Similar results were disclosed when APRIL and BAFFR haplotypes were compared between IgAV patients and controls and between IgAV patients stratified according to the clinical characteristics mentioned above. Our results suggest that BAFF, APRIL and BAFFR do not contribute to the genetic network underlying IgAV.
Collapse
Affiliation(s)
- Diana Prieto-Peña
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain
| | - Fernanda Genre
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain
| | - Sara Remuzgo-Martínez
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain
| | - Verónica Pulito-Cueto
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain
| | - Belén Atienza-Mateo
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain.,`López Albo´ Post-Residency Programme, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Javier Llorca
- Epidemiology and Computational Biology Department, School of Medicine, Universidad de Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain
| | | | | | - Leticia Lera-Gómez
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain
| | - María Teresa Leonardo
- Division of Paediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Ana Peñalba
- Division of Paediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Javier Narváez
- Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
| | - Luis Martín-Penagos
- Division of Nephrology, Hospital Universitario Marqués de Valdecilla, IDIVAL-REDINREN, Santander, Spain
| | - Emilio Rodrigo
- Division of Nephrology, Hospital Universitario Marqués de Valdecilla, IDIVAL-REDINREN, Santander, Spain
| | | | - Luis Caminal-Montero
- Internal Medicine Dept, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
| | - Paz Collado
- Division of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain
| | | | - Diego de Argila
- Division of Dermatology, Hospital Universitario de La Princesa, Madrid, Spain
| | - Esteban Rubio
- Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - Manuel León Luque
- Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | | | | | - Oreste Gualillo
- SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
| | - Javier Martín
- Instituto de Parasitología y Biomedicina 'López-Neyra', CSIC, PTS Granada, Granada, Spain
| | - Santos Castañeda
- Rheumatology Department, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain
| | - Ricardo Blanco
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain
| | - Miguel A González-Gay
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain.,School of Medicine, Universidad de Cantabria, Santander, Spain.,Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Raquel López-Mejías
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain.
| |
Collapse
|
12
|
Tornero-Molina J, Alperi-López M, Castellví I, de Agustín-de Oro JJ, Escudero A, García-Vicuña R, González-Gay MÁ, Hidalgo C, Rubio E, Sanmartí R, Casamira N, Calvo-Alén J. Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis. Reumatol Clin (Engl Ed) 2020; 18:S1699-258X(20)30200-X. [PMID: 33041228 DOI: 10.1016/j.reuma.2020.08.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Revised: 07/16/2020] [Accepted: 08/20/2020] [Indexed: 02/07/2023]
Abstract
OBJECTIVE We aimed to develop recommendations for the management of methotrexate (MTX) when considering the combination with biological (b) or targeted synthetic (ts) disease modifying drugs (DMARDs) in rheumatoid arthritis (RA). METHODS Eleven experts on RA were selected. Two coordinators formulated 13 questions about the combination therapy of MTX with bDMARDs or tsDMARDs. A systematic review was conducted to answer the questions. Inclusion and exclusion criteria were established as well as the search strategies (Medline, Embase and the Cochrane Library were searched up to January 2019). Two reviewers selected the articles and collected data. Simultaneously, EULAR and ACR meeting abstracts were evaluated. Based on this evidence, the coordinators proposed preliminary recommendations that the experts discussed and voted in a nominal group meeting. The level of evidence and grade of recommendation was established using the Oxford Center for Evidence Based Medicine and the level of agreement with a Delphi. Agreement was established if at least 80% of the experts voted 'yes' (yes/no). RESULTS The systematic review retrieved 513 citations of which 61 were finally included. A total of 10 recommendations were generated, voted and accepted. The level of agreement was very high in all of them and it was achieved in the first Delphi round. Final recommendations cover aspects such as the optimal MTX dosage, tapering strategy or patients' risk management. CONCLUSIONS This document is intended to help clinicians solve usual clinical questions and facilitate decision making when treating RA patients with MTX in combination with bDMARDs or tsDMARDs.
Collapse
Affiliation(s)
| | | | - Ivan Castellví
- Servicio de Reumatología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | | | - Alejandro Escudero
- Servicio de Reumatología, Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain
| | | | | | - Cristina Hidalgo
- Servicio de Reumatología, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
| | - Esteban Rubio
- Servicio de Reumatología, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - Raimon Sanmartí
- Servicio de Reumatología, Hospital Universitari Clínic, Barcelona, Spain
| | - Núria Casamira
- Departamento Médico, Laboratorios Gebro Pharma, Barcelona, Spain
| | - Jaime Calvo-Alén
- Servicio de Reumatología, Hospital Universitario Araba, Vitoria-Gasteiz, Spain
| |
Collapse
|
13
|
Remuzgo Martinez S, Genre F, Pulito-Cueto V, Prieto-Peña D, Atienza-Mateo B, Sevilla B, Llorca J, Ortego N, Lera-Gómez L, Leonardo M, Peñalba A, Cabero MJ, Martín-Penagos L, Miranda-Filloy JA, Navas Parejo A, Sanchez Perez J, Aragües M, Rubio E, Leon Luque M, Blanco-Madrigal JM, Galindez E, Martin Ibanez J, Castañeda S, Blanco R, González-Gay ,, MA, López-Mejías R. AB0012 ROLE OF IRF5 GENE ON THE PATHOGENESIS OF IMMUNOGLOBULIN-A VASCULITIS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Interferon signaling pathway plays a relevant role in autoimmunity. Genetic variants in theinterferon regulatory factor (IRF) 5gene, that encodes the major regulator of the type I interferon induction [1], have been related to the development of several inflammatory diseases [2].Objectives:To determine the influence ofIRF5on Immunoglobulin-A vasculitis (IgAV), an inflammatory vascular disease.Methods:ThreeIRF5polymorphisms (rs2004640, rs2070197 and rs10954213) representative of 3 different haplotype blocks were genotyped in 372 Caucasian patients with IgAV and 876 sex and ethnically matched healthy controls.Results:No statistically significant differences between patients with IgAV and controls were observed when eachIRF5polymorphism was analyzed independently. Similarly, no statistically significant differences between patients with IgAV and controls were found whenIRF5polymorphisms were evaluated combined conforming haplotypes. Additionally, there were no statistically significant differences in genotype, allele and haplotype frequencies ofIRF5when patients with IgAV were stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations.Conclusion:Our results do not support an influence ofIRF5on the pathogenesis of IgAV.References:[1]Nat Immunol 2011; 12: 231-8;[2]Arthritis Res Ther 2014; 16: R146.Acknowledgments:This study was supported by European Union FEDER funds and “Fondo de Investigaciones Sanitarias” (grant PI18/00042) from ‘Instituto de Salud Carlos III’ (ISCIII, Health Ministry, Spain). RL-M is a recipient of a Miguel Servet type I programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, `Investing in your future´) (grant CP16/00033). SR-M is supported by funds of the RETICS Program (RD16/0012/0009) (ISCIII, co-funded by the European Regional Development Fund (ERDF)). VP-C is supported by a pre-doctoral grant from IDIVAL (PREVAL 18/01). LL-G is supported by funds of PI18/00042 (ISCIII, co-funded by ERDF).Disclosure of Interests:Sara Remuzgo Martinez: None declared, Fernanda Genre: None declared, Verónica Pulito-Cueto: None declared, D. Prieto-Peña: None declared, Belén Atienza-Mateo: None declared, Belén Sevilla: None declared, Javier Llorca: None declared, Norberto Ortego: None declared, Leticia Lera-Gómez: None declared, Maite Leonardo: None declared, Ana Peñalba: None declared, María Jesús Cabero: None declared, Luis Martín-Penagos: None declared, Jose Alberto Miranda-Filloy: None declared, Antonio Navas Parejo: None declared, Javier Sanchez Perez: None declared, Maximiliano Aragües: None declared, Esteban Rubio: None declared, MANUEL LEON LUQUE: None declared, Juan María Blanco-Madrigal: None declared, E. Galindez: None declared, Javier Martin Ibanez: None declared, Santos Castañeda: None declared, Ricardo Blanco Grant/research support from: Abbvie, MSD and Roche, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen, Lilly and MSD, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Raquel López-Mejías: None declared
Collapse
|
14
|
Sanz Sanz J, Beltrán E, Díaz-Miguel Pérez MC, Fernández-Carballido C, Galíndez E, García Porrua C, Gratacós J, Medina J, Queiro R, Ramírez J, Reina D, Rodríguez Lozano C, Rodríguez Martínez FJ, Rubio E, Veroz R. Norma de calidad para el manejo del paciente con artritis psoriásica: proyecto QUANTUM. ACTA ACUST UNITED AC 2020; 16:203-215. [DOI: 10.1016/j.reuma.2018.06.011] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2018] [Revised: 06/12/2018] [Accepted: 06/26/2018] [Indexed: 12/27/2022]
|
15
|
López-Mejías R, Genre F, Remuzgo-Martínez S, Pulito-Cueto V, Sevilla-Pérez B, Llorca J, Ortego-Centeno N, Mijares V, Lera-Gómez L, Leonardo MT, Peñalba A, Cabero MJ, Martín-Penagos L, Miranda-Filloy JA, Navas Parejo A, Sánchez Pérez J, de Argila D, Rubio E, León Luque M, Blanco-Madrigal JM, Galíndez-Agirregoikoa E, Martín J, Blanco R, Castañeda S, González-Gay MA. Influence of IL17A gene on the pathogenesis of immunoglobulin-A vasculitis. Clin Exp Rheumatol 2020; 38 Suppl 124:166-170. [PMID: 32242803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2019] [Accepted: 02/03/2020] [Indexed: 06/11/2023]
Abstract
OBJECTIVES Cytokines signaling pathway genes represent a key component of the genetic network implicated in the pathogenesis of immunoglobulin-A vasculitis (IgAV), an inflammatory vascular pathology. Interleukin (IL)17A is described as a genetic risk locus for some autoimmune diseases, such as giant cell arteritis and spondyloarthritis. Accordingly, we aimed to determine the potential influence of IL17A on the pathogenesis of IgAV. METHODS Five IL17A tag polymorphisms (rs4711998, rs8193036, rs3819024, rs2275913 and rs7747909), which cover the major variability of this gene, were genotyped in 360 Caucasian patients with IgAV and 1,003 sex and ethnically matched healthy controls using TaqMan probes. RESULTS No statistically significant differences between patients with IgAV and healthy controls were observed when each IL17A genetic variant was analysed independently. Similarly, no statistically significant differences between patients with IgAV and healthy controls were found when the five IL17A polymorphisms were evaluated combined conforming haplotypes. In addition, there were no statistically significant differences in genotype, allele and haplotype frequencies of IL17A when patients with IgAV were stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations. CONCLUSIONS Our results do not support an influence of IL17A on the pathogenesis of IgAV.
Collapse
Affiliation(s)
- Raquel López-Mejías
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain.
| | - Fernanda Genre
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain
| | - Sara Remuzgo-Martínez
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain
| | - Verónica Pulito-Cueto
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain
| | | | - Javier Llorca
- Epidemiology and Computational Biology Department, School of Medicine, Universidad de Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain
| | | | - Verónica Mijares
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain
| | - Leticia Lera-Gómez
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain
| | - Maria Teresa Leonardo
- Division of Paediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Ana Peñalba
- Division of Paediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - María Jesús Cabero
- Division of Paediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Luis Martín-Penagos
- Nephrology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL-REDINREN, Santander, Spain
| | | | | | - Javier Sánchez Pérez
- Dermatology Department, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain
| | - Diego de Argila
- Dermatology Department, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain
| | - Esteban Rubio
- Rheumatology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - Manuel León Luque
- Rheumatology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | | | | | - Javier Martín
- Instituto de Parasitología y Biomedicina 'López-Neyra', CSIC, PTS Granada, Granada, Spain
| | - Ricardo Blanco
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain
| | - Santos Castañeda
- Rheumatology Department, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain
| | - Miguel A González-Gay
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; and Universidad de Cantabria, Santander, Spain.
| |
Collapse
|
16
|
Genre F, Remuzgo-Martínez S, Prieto-Peña D, Atienza-Mateo B, Pulito-Cueto V, Llorca J, Sevilla-Pérez B, Ortego-Centeno N, Lera-Gómez L, Leonardo MT, Peñalba A, Cabero MJ, Martín-Penagos L, Miranda-Filloy JA, Navas Parejo A, Sánchez Pérez J, de Argila D, Rubio E, León Luque M, Blanco-Madrigal JM, Galíndez-Agirregoikoa E, Blanco R, Gualillo O, Martín J, Castañeda S, González-Gay MA, López-Mejías R. Role of IRF5 in the pathogenesis of immunoglobulin-A vasculitis. Clin Exp Rheumatol 2020; 38 Suppl 124:182-187. [PMID: 32441646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Accepted: 04/07/2020] [Indexed: 06/11/2023]
Abstract
OBJECTIVES Interferon regulatory factor 5 (IRF5) is a major regulator of type I interferon induction and is also critical to produce pro-inflammatory cytokines. An influence of IRF5 genetic variants on the increased risk of immune-mediated diseases has been described. Accordingly, we aimed to evaluate the implication of IRF5 in the pathogenesis of Immunoglobulin-A vasculitis (IgAV), an inflammatory vascular pathology. METHODS Three tag genetic variants (rs2004640, rs2070197 and rs10954213), representative of 3 different haplotype blocks within IRF5, were genotyped in 372 Caucasian patients with IgAV and 876 sex and ethnically matched healthy controls by TaqMan assays. RESULTS No significant differences in the genotype and allele frequencies between patients with IgAV and healthy controls were observed when each IRF5 polymorphism was evaluated independently. Likewise, no significant differences between patients with IgAV and healthy controls were found when we assessed the three IRF5 polymorphisms combined, conforming haplotypes. In addition, there were no significant differences in genotype, allele and haplotype frequencies of IRF5 when patients with IgAV were stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations. CONCLUSIONS Our results do not support an influence of IRF5 on the pathogenesis of IgAV.
Collapse
Affiliation(s)
- Fernanda Genre
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Sara Remuzgo-Martínez
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Diana Prieto-Peña
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Belén Atienza-Mateo
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Verónica Pulito-Cueto
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Javier Llorca
- Epidemiology and Computational Biology Department, School of Medicine, Universidad de Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain
| | | | | | - Leticia Lera-Gómez
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - María Teresa Leonardo
- Division of Paediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Ana Peñalba
- Division of Paediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - María Jesús Cabero
- Division of Paediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Luis Martín-Penagos
- Nephrology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL-REDINREN, Santander, Spain
| | | | | | | | - Diego de Argila
- Dermatology Department, Hospital Universitario de La Princesa, Madrid, Spain
| | - Esteban Rubio
- Rheumatology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - Manuel León Luque
- Rheumatology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | | | | | - Ricardo Blanco
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Oreste Gualillo
- Servizo Galego de Saude and Instituto de Investigación Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
| | - Javier Martín
- Instituto de Parasitología y Biomedicina 'López-Neyra', CSIC, PTS Granada, Granada, Spain
| | - Santos Castañeda
- Rheumatology Department, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain
| | - Miguel A González-Gay
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander; School of Medicine, Universidad de Cantabria, Santander, Spain; and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
| | - Raquel López-Mejías
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
| |
Collapse
|
17
|
Delgado B, Martinez-Monteagudo MC, Ruiz-Esteban C, Rubio E. Latent Class Analysis of School Refusal Behavior and Its Relationship With Cyberbullying During Adolescence. Front Psychol 2019; 10:1916. [PMID: 31474920 PMCID: PMC6706820 DOI: 10.3389/fpsyg.2019.01916] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2019] [Accepted: 08/05/2019] [Indexed: 11/13/2022] Open
Abstract
Cyberbullying is a common relational problem having negative repercussions on the academic performance of adolescents. Numerous questions remain to be answered with regard to the relationship between cyberbullying and school refusal behavior. This study examines school refusal profiles (measured by School Refusal Assessment Scale-Revised) and assesses whether these profiles vary with respect to the level of victimization, aggression, aggression-victimization, and observation of cyberbullying (measured with the Screening of Harassment among Peers). The sample consisted of 1,102 Spanish high school students, aged 12–18 (M = 14.30, SD = 1.71). Latent class analysis revealed three school refusal behavior profiles: non-school refusal behavior, school refusal behavior by negative reinforcements (oriented to the avoidance of social evaluation and negative affectivity in school situations), and school refusal behavior by positive reinforcements (oriented to obtaining the attention of others with significant or tangible reinforcements). The ANOVA found statistically significant differences for all cyberbullying behaviors. Students with school refusal by negative reinforcements had significantly higher mean scores as compared to the other profiles in victimization, aggression, aggression-victimization, and observation behaviors, while the levels of cyberbullying were similar between students without school refusal and students with school refusal behavior by positive reinforcements. These findings underscore the need to consider priority interventions to prevent cyberbullying in children who refuse school for the purpose of avoiding situations of anxiety and negative emotions.
Collapse
Affiliation(s)
- B Delgado
- Department of Developmental Psychology and Didactic, Faculty of Education, University of Alicante, Alicante, Spain
| | - M C Martinez-Monteagudo
- Department of Developmental Psychology and Didactic, Faculty of Education, University of Alicante, Alicante, Spain
| | - C Ruiz-Esteban
- Department of Developmental Psychology and Education, Faculty of Psychology, University of Murcia, Murcia, Spain
| | - E Rubio
- Department of Developmental Psychology and Didactic, Faculty of Education, University of Alicante, Alicante, Spain
| |
Collapse
|
18
|
López A, Baguer B, Goñi P, Rubio E, Gómez J, Mosteo R, Ormad MP. Assessment of the methodologies used in microbiological control of sewage sludge. Waste Manag 2019; 96:168-174. [PMID: 31376961 DOI: 10.1016/j.wasman.2019.07.024] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/02/2019] [Revised: 06/28/2019] [Accepted: 07/14/2019] [Indexed: 06/10/2023]
Abstract
Sewage sludge usually contains potentially polluting substances such as heavy metals, organic pollutants and various organisms including bacteria, protozoa, helminths, viruses and algae, some of which may be pathogenic. Certain of these pathogens could be transferred to the soil if the sludge is used on agricultural or land recovery applications. For its application on agricultural land, sewage sludge must comply with the limits established in the legislation, which in Europe does not include quality standards regarding microbiological parameters. Nevertheless, the presence of pathogens could limit its agricultural use, as it could pose a risk to human, animal and environmental health. This study compares 4 different methodologies used in microbiological analysis in order to identify the most efficient and reliable method on determining bacteria in sewage sludge. Escherichia coli and Enterococcus faecium are used as bacterial indicators. The results obtained in this work indicate that results obtained with three different plate count methods cannot be comparable with those obtained with the MPN method. The membrane filtration method is recommended for its high precision and sensitivity, both in low and high bacterial loads. It is also concluded that it would be necessary to establish the quality standard in concordance with the method used.
Collapse
Affiliation(s)
- A López
- Water and Environmental Health Research Group, Environmental Sciences Institute (IUCA), Department of Chemical Engineering and Environmental Technologies, School of Engineering and Architecture, University of Zaragoza, Calle María de Luna 3, 50018 Zaragoza, Spain.
| | - B Baguer
- Water and Environmental Health Research Group, Environmental Sciences Institute (IUCA), Department of Chemical Engineering and Environmental Technologies, School of Engineering and Architecture, University of Zaragoza, Calle María de Luna 3, 50018 Zaragoza, Spain
| | - P Goñi
- Department of Microbiology, Preventive Medicine and Public Health, Water and Environmental Health Research Group, Environmental Sciences Institute (IUCA), Faculty of Medicine, University of Zaragoza, Calle Domingo Miral, 50009 Zaragoza, Spain
| | - E Rubio
- Department of Microbiology, Preventive Medicine and Public Health, Water and Environmental Health Research Group, Environmental Sciences Institute (IUCA), Faculty of Medicine, University of Zaragoza, Calle Domingo Miral, 50009 Zaragoza, Spain
| | - J Gómez
- Navarra de Infraestructuras Locales S.A (NILSA), Avenida Barañain 22, 31008 Pamplona, Spain
| | - R Mosteo
- Water and Environmental Health Research Group, Environmental Sciences Institute (IUCA), Department of Chemical Engineering and Environmental Technologies, School of Engineering and Architecture, University of Zaragoza, Calle María de Luna 3, 50018 Zaragoza, Spain
| | - M P Ormad
- Water and Environmental Health Research Group, Environmental Sciences Institute (IUCA), Department of Chemical Engineering and Environmental Technologies, School of Engineering and Architecture, University of Zaragoza, Calle María de Luna 3, 50018 Zaragoza, Spain
| |
Collapse
|
19
|
Crous P, Carnegie A, Wingfield M, Sharma R, Mughini G, Noordeloos M, Santini A, Shouche Y, Bezerra J, Dima B, Guarnaccia V, Imrefi I, Jurjević Ž, Knapp D, Kovács G, Magistà D, Perrone G, Rämä T, Rebriev Y, Shivas R, Singh S, Souza-Motta C, Thangavel R, Adhapure N, Alexandrova A, Alfenas A, Alfenas R, Alvarado P, Alves A, Andrade D, Andrade J, Barbosa R, Barili A, Barnes C, Baseia I, Bellanger JM, Berlanas C, Bessette A, Bessette A, Biketova A, Bomfim F, Brandrud T, Bransgrove K, Brito A, Cano-Lira J, Cantillo T, Cavalcanti A, Cheewangkoon R, Chikowski R, Conforto C, Cordeiro T, Craine J, Cruz R, Damm U, de Oliveira R, de Souza J, de Souza H, Dearnaley J, Dimitrov R, Dovana F, Erhard A, Esteve-Raventós F, Félix C, Ferisin G, Fernandes R, Ferreira R, Ferro L, Figueiredo C, Frank J, Freire K, García D, Gené J, Gêsiorska A, Gibertoni T, Gondra R, Gouliamova D, Gramaje D, Guard F, Gusmão L, Haitook S, Hirooka Y, Houbraken J, Hubka V, Inamdar A, Iturriaga T, Iturrieta-González I, Jadan M, Jiang N, Justo A, Kachalkin A, Kapitonov V, Karadelev M, Karakehian J, Kasuya T, Kautmanová I, Kruse J, Kušan I, Kuznetsova T, Landell M, Larsson KH, Lee H, Lima D, Lira C, Machado A, Madrid H, Magalhães O, Majerova H, Malysheva E, Mapperson R, Marbach P, Martín M, Martín-Sanz A, Matočec N, McTaggart A, Mello J, Melo R, Mešić A, Michereff S, Miller A, Minoshima A, Molinero-Ruiz L, Morozova O, Mosoh D, Nabe M, Naik R, Nara K, Nascimento S, Neves R, Olariaga I, Oliveira R, Oliveira T, Ono T, Ordoñez M, Ottoni ADM, Paiva L, Pancorbo F, Pant B, Pawłowska J, Peterson S, Raudabaugh D, Rodríguez-Andrade E, Rubio E, Rusevska K, Santiago A, Santos A, Santos C, Sazanova N, Shah S, Sharma J, Silva B, Siquier J, Sonawane M, Stchigel A, Svetasheva T, Tamakeaw N, Telleria M, Tiago P, Tian C, Tkalčec Z, Tomashevskaya M, Truong H, Vecherskii M, Visagie C, Vizzini A, Yilmaz N, Zmitrovich I, Zvyagina E, Boekhout T, Kehlet T, Læssøe T, Groenewald J. Fungal Planet description sheets: 868-950. Persoonia 2019; 42:291-473. [PMID: 31551622 PMCID: PMC6712538 DOI: 10.3767/persoonia.2019.42.11] [Citation(s) in RCA: 90] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/01/2019] [Accepted: 05/10/2019] [Indexed: 12/11/2022]
Abstract
Novel species of fungi described in this study include those from various countries as follows: Australia, Chaetomella pseudocircinoseta and Coniella pseudodiospyri on Eucalyptus microcorys leaves, Cladophialophora eucalypti, Teratosphaeria dunnii and Vermiculariopsiella dunnii on Eucalyptus dunnii leaves, Cylindrium grande and Hypsotheca eucalyptorum on Eucalyptus grandis leaves, Elsinoe salignae on Eucalyptus saligna leaves, Marasmius lebeliae on litter of regenerating subtropical rainforest, Phialoseptomonium eucalypti (incl. Phialoseptomonium gen. nov.) on Eucalyptus grandis × camaldulensis leaves, Phlogicylindrium pawpawense on Eucalyptus tereticornis leaves, Phyllosticta longicauda as an endophyte from healthy Eustrephus latifolius leaves, Pseudosydowia eucalyptorum on Eucalyptus sp. leaves, Saitozyma wallum on Banksia aemula leaves, Teratosphaeria henryi on Corymbia henryi leaves. Brazil, Aspergillus bezerrae, Backusella azygospora, Mariannaea terricola and Talaromyces pernambucoensis from soil, Calonectria matogrossensis on Eucalyptus urophylla leaves, Calvatia brasiliensis on soil, Carcinomyces nordestinensis on Bromelia antiacantha leaves, Dendryphiella stromaticola on small branches of an unidentified plant, Nigrospora brasiliensis on Nopalea cochenillifera leaves, Penicillium alagoense as a leaf endophyte on a Miconia sp., Podosordaria nigrobrunnea on dung, Spegazzinia bromeliacearum as a leaf endophyte on Tilandsia catimbauensis, Xylobolus brasiliensis on decaying wood. Bulgaria, Kazachstania molopis from the gut of the beetle Molops piceus. Croatia, Mollisia endocrystallina from a fallen decorticated Picea abies tree trunk. Ecuador, Hygrocybe rodomaculata on soil. Hungary, Alfoldia vorosii (incl. Alfoldia gen. nov.) from Juniperus communis roots, Kiskunsagia ubrizsyi (incl. Kiskunsagia gen. nov.) from Fumana procumbens roots. India, Aureobasidium tremulum as laboratory contaminant, Leucosporidium himalayensis and Naganishia indica from windblown dust on glaciers. Italy, Neodevriesia cycadicola on Cycas sp. leaves, Pseudocercospora pseudomyrticola on Myrtus communis leaves, Ramularia pistaciae on Pistacia lentiscus leaves, Neognomoniopsis quercina (incl. Neognomoniopsis gen. nov.) on Quercus ilex leaves. Japan, Diaporthe fructicola on Passiflora edulis × P. edulis f. flavicarpa fruit, Entoloma nipponicum on leaf litter in a mixed Cryptomeria japonica and Acer spp. forest. Macedonia, Astraeus macedonicus on soil. Malaysia, Fusicladium eucalyptigenum on Eucalyptus sp. twigs, Neoacrodontiella eucalypti (incl. Neoacrodontiella gen. nov.) on Eucalyptus urophylla leaves. Mozambique, Meliola gorongosensis on dead Philenoptera violacea leaflets. Nepal, Coniochaeta dendrobiicola from Dendriobium lognicornu roots. New Zealand, Neodevriesia sexualis and Thozetella neonivea on Archontophoenix cunninghamiana leaves. Norway, Calophoma sandfjordenica from a piece of board on a rocky shoreline, Clavaria parvispora on soil, Didymella finnmarkica from a piece of Pinus sylvestris driftwood. Poland, Sugiyamaella trypani from soil. Portugal, Colletotrichum feijoicola from Acca sellowiana. Russia, Crepidotus tobolensis on Populus tremula debris, Entoloma ekaterinae, Entoloma erhardii and Suillus gastroflavus on soil, Nakazawaea ambrosiae from the galleries of Ips typographus under the bark of Picea abies. Slovenia, Pluteus ludwigii on twigs of broadleaved trees. South Africa, Anungitiomyces stellenboschiensis (incl. Anungitiomyces gen. nov.) and Niesslia stellenboschiana on Eucalyptus sp. leaves, Beltraniella pseudoportoricensis on Podocarpus falcatus leaf litter, Corynespora encephalarti on Encephalartos sp. leaves, Cytospora pavettae on Pavetta revoluta leaves, Helminthosporium erythrinicola on Erythrina humeana leaves, Helminthosporium syzygii on a Syzygium sp. bark canker, Libertasomyces aloeticus on Aloe sp. leaves, Penicillium lunae from Musa sp. fruit, Phyllosticta lauridiae on Lauridia tetragona leaves, Pseudotruncatella bolusanthi (incl. Pseudotruncatellaceae fam. nov.) and Dactylella bolusanthi on Bolusanthus speciosus leaves. Spain, Apenidiella foetida on submerged plant debris, Inocybe grammatoides on Quercus ilex subsp. ilex forest humus, Ossicaulis salomii on soil, Phialemonium guarroi from soil. Thailand, Pantospora chromolaenae on Chromolaena odorata leaves. Ukraine, Cadophora helianthi from Helianthus annuus stems. USA, Boletus pseudopinophilus on soil under slash pine, Botryotrichum foricae, Penicillium americanum and Penicillium minnesotense from air. Vietnam, Lycoperdon vietnamense on soil. Morphological and culture characteristics are supported by DNA barcodes.
Collapse
Affiliation(s)
- P.W. Crous
- Westerdijk Fungal Biodiversity Institute, P.O. Box 85167, 3508 AD Utrecht, The Netherlands
- Department of Biochemistry, Genetics and Microbiology, Forestry and Agricultural Biotechnology Institute (FABI), Faculty of Natural and Agricultural Sciences, University of Pretoria, Private Bag X20, Hatfield 0028, Pretoria, South Africa
| | - A.J. Carnegie
- Forest Health & Biosecurity, NSW Department of Primary Industries, Forestry, Level 12, 10 Valentine Ave, Parramatta NSW 2150, Australia
| | - M.J. Wingfield
- Department of Biochemistry, Genetics and Microbiology, Forestry and Agricultural Biotechnology Institute (FABI), Faculty of Natural and Agricultural Sciences, University of Pretoria, Private Bag X20, Hatfield 0028, Pretoria, South Africa
| | - R. Sharma
- National Centre for Microbial Resource (NCMR), National Centre for Cell Science, S.P. Pune University, Ganeshkhind, Pune 411 007, Maharashtra, India
| | - G. Mughini
- Research Center for Forestry and Wood - C.R.E.A., Via Valle della Quistione 27, 00166 Rome, Italy
| | - M.E. Noordeloos
- Naturalis Biodiversity Center, section Botany, P.O. Box 9517, 2300 RA Leiden, The Netherlands
| | - A. Santini
- Institute for Sustainable Plant Protection - C.N.R., Via Madonna del Piano 10, 50019 Sesto fiorentino (FI), Italy
| | - Y.S. Shouche
- National Centre for Microbial Resource (NCMR), National Centre for Cell Science, S.P. Pune University, Ganeshkhind, Pune 411 007, Maharashtra, India
| | - J.D.P. Bezerra
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - B. Dima
- Department of Plant Anatomy, Institute of Biology, Eötvös Loránd University, 1117 Budapest, Pázmány Péter sétány 1/C, Hungary
| | - V. Guarnaccia
- DiSAFA, University of Torino, Largo Paolo Braccini, 2, 10095 Grugliasco, TO, Italy
| | - I. Imrefi
- Department of Plant Anatomy, Institute of Biology, Eötvös Loránd University, 1117 Budapest, Pázmány Péter sétány 1/C, Hungary
| | - Ž. Jurjević
- EMSL Analytical, Inc., 200 Route 130 North, Cinnaminson, NJ 08077, USA
| | - D.G. Knapp
- Department of Plant Anatomy, Institute of Biology, Eötvös Loránd University, 1117 Budapest, Pázmány Péter sétány 1/C, Hungary
| | - G.M. Kovács
- Department of Plant Anatomy, Institute of Biology, Eötvös Loránd University, 1117 Budapest, Pázmány Péter sétány 1/C, Hungary
| | - D. Magistà
- Institute of Sciences of Food Production, CNR, Via Amendola 122/O, 70126 Bari, Italy
| | - G. Perrone
- Institute of Sciences of Food Production, CNR, Via Amendola 122/O, 70126 Bari, Italy
| | - T. Rämä
- Marbio, Norwegian College of Fishery Science, University of Tromsø - The Arctic University of Norway
| | - Y.A. Rebriev
- South Scientific Center of the Russian Academy of Sciences, Rostov-on-Don, Russia
| | - R.G. Shivas
- Centre for Crop Health, University of Southern Queensland, Toowoomba 4350, Australia
| | - S.M. Singh
- National Centre for Antarctic and Ocean Research, Headland Sada, Vasco-da-Gama-403 804, Goa, India
- Banaras Hindu University (BHU), Uttar Pradesh, India
| | - C.M. Souza-Motta
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - R. Thangavel
- Plant Health and Environment Laboratory, Ministry for Primary Industries, P.O. Box 2095, Auckland 1140, New Zealand
| | - N.N. Adhapure
- Department of Biotechnology and Microbiology, Vivekanand Arts, Sardar Dalipsingh Commerce and Science College, Aurangabad 431001, Maharashtra, India
| | - A.V. Alexandrova
- Lomonosov Moscow State University (MSU), Faculty of Biology, 119234, 1, 12 Leninskie Gory Str., Moscow, Russia
- Joint Russian-Vietnamese Tropical Research and Technological Center, Hanoi, Vietnam
| | - A.C. Alfenas
- Departamento de Fitopatologia, Universidade Federal de Viçosa, Viçosa, Brazil
| | - R.F. Alfenas
- Departamento de Engenharia Florestal, Universidade Federal de Mato Grosso, Cuiabá, Brazil
| | - P. Alvarado
- ALVALAB, Avda. de Bruselas 2-3B, 33011 Oviedo, Spain
| | - A.L. Alves
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - D.A. Andrade
- Instituto de Ciências Biológicas e da Saúde – ICBS, Universidade Federal de Alagoas, Maceió, Brazil
| | - J.P. Andrade
- Universidade Estadual de Feira de Santana, Av. Transnordestina, S/N – Novo Horizonte, 44036-900 Feira de Santana, BA, Brazil
| | - R.N. Barbosa
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - A. Barili
- Escuela de Ciencias Biológicas, Pontificia Universidad Católica del Ecuador, Av. 12 de octubre 1076 y Roca, Quito, Ecuador
| | - C.W. Barnes
- Escuela de Ciencias Biológicas, Pontificia Universidad Católica del Ecuador, Av. 12 de octubre 1076 y Roca, Quito, Ecuador
| | - I.G. Baseia
- Departamento Botânica e Zoologia, Centro de Biociências, Universidade Federal do Rio Grande do Norte, Campus Universitário, 59072-970, Natal, RN, Brazil
| | - J.-M. Bellanger
- CEFE – CNRS – Université de Montpellier – Université Paul-Valéry Montpellier – EPHE – IRD – INSERM, Campus CNRS, 1919 Route de Mende, 34293 Montpellier, France
| | - C. Berlanas
- Instituto de Ciencias de la Vid y del Vino (Gobierno de La Rioja-CSIC-Universidad de La Rioja), Ctra. LO-20, Salida 13, 26007 Logroño, La Rioja, Spain
| | | | | | - A.Yu. Biketova
- Synthetic and Systems Biology Unit, Biological Research Centre, Hungarian Academy of Sciences, H-6726 Szeged, Hungary
| | - F.S. Bomfim
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - T.E. Brandrud
- Norwegian Institute for Nature Research, Gaustadalléen 21, NO-0349 Oslo, Norway
| | - K. Bransgrove
- Plant Pathology Herbarium, Department of Agriculture and Fisheries, Dutton Park 4102, Queensland, Australia
| | - A.C.Q. Brito
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - J.F. Cano-Lira
- Mycology Unit, Medical School and IISPV, Universitat Rovira i Virgili (URV), Sant Llorenç 21, 43201 Reus, Tarragona, Spain
| | - T. Cantillo
- Departamento de Ciências Biológicas, Universidade Estadual de Feira de Santana, Av. Transnordestina, S/N – Novo Horizonte, 44036-900 Feira de Santana, BA, Brazil
| | - A.D. Cavalcanti
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - R. Cheewangkoon
- Department of Entomology and Plant Pathology, Faculty of Agriculture, Chiang Mai University, Chiang Mai 50200, Thailand
| | - R.S. Chikowski
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - C. Conforto
- Instituto de Patología Vegetal, Instituto Nacional de Tecnología Agropecuaria, Córdoba, Argentina
| | - T.R.L. Cordeiro
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - J.D. Craine
- 5320 N. Peachtree Road, Dunwoody, GA 30338, USA
| | - R. Cruz
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - U. Damm
- Senckenberg Museum of Natural History Görlitz, PF 300 154, 02806 Görlitz, Germany
| | - R.J.V. de Oliveira
- Comissão Executiva do Plano da Lavoura Cacaueira (CEPLAC)/CEPEC, Itabuna, Bahia, Brazil
| | | | - H.G. de Souza
- Recôncavo da Bahia Federal University, Bahia, Brazil
| | - J.D.W. Dearnaley
- Centre for Crop Health, University of Southern Queensland, Toowoomba 4350, Australia
| | - R.A. Dimitrov
- National Center of Infectious and Parasitic Diseases, 26 Yanko Sakazov blvd, Sofia 1504, Bulgaria
| | - F. Dovana
- Department of Life Sciences and Systems Biology, University of Turin, Viale P.A. Mattioli 25, 10125, Torino, Italy
| | - A. Erhard
- EMSL Analytical, Inc., 200 Route 130 North, Cinnaminson, NJ 08077, USA
| | - F. Esteve-Raventós
- Departamento de Ciencias de la Vida (Area de Botánica), Universidad de Alcalá, 28805 Alcalá de Henares, Madrid, Spain
| | - C.R. Félix
- Instituto de Ciências Biológicas e da Saúde – ICBS, Universidade Federal de Alagoas, Maceió, Brazil
| | - G. Ferisin
- Via A. Vespucci 7, 1537, 33052 Cervignano del Friuli (UD), Italy
| | - R.A. Fernandes
- Departamento de Fitopatologia, Universidade Federal de Brasilia, Brasilia, Brazil
| | - R.J. Ferreira
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - L.O. Ferro
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | | | - J.L. Frank
- Department of Biology, Southern Oregon University, Ashland OR 97520, USA
| | - K.T.L.S. Freire
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - D. García
- Mycology Unit, Medical School and IISPV, Universitat Rovira i Virgili (URV), Sant Llorenç 21, 43201 Reus, Tarragona, Spain
| | - J. Gené
- Mycology Unit, Medical School and IISPV, Universitat Rovira i Virgili (URV), Sant Llorenç 21, 43201 Reus, Tarragona, Spain
| | - A. Gêsiorska
- Department of Molecular Phylogenetics and Evolution, Faculty of Biology, Biological and Chemical Research Centre, University of Warsaw, ul. Zwirki i Wigury 101, 02-089 Warsaw, Poland
| | - T.B. Gibertoni
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - R.A.G. Gondra
- University Utrecht, P.O. Box 80125, 3508 TC Utrecht, The Netherlands
| | - D.E. Gouliamova
- The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 26 Acad. Georgi Bonchev, Sofia 1113, Bulgaria
| | - D. Gramaje
- Instituto de Ciencias de la Vid y del Vino (Gobierno de La Rioja-CSIC-Universidad de La Rioja), Ctra. LO-20, Salida 13, 26007 Logroño, La Rioja, Spain
| | | | - L.F.P. Gusmão
- Departamento de Ciências Biológicas, Universidade Estadual de Feira de Santana, Av. Transnordestina, S/N – Novo Horizonte, 44036-900 Feira de Santana, BA, Brazil
| | - S. Haitook
- Department of Entomology and Plant Pathology, Faculty of Agriculture, Chiang Mai University, Chiang Mai 50200, Thailand
| | - Y. Hirooka
- Department of Clinical Plant Science, Faculty of Bioscience, Hosei University, 3-7-2 Kajino-cho, Koganei, Tokyo, Japan
| | - J. Houbraken
- Westerdijk Fungal Biodiversity Institute, P.O. Box 85167, 3508 AD Utrecht, The Netherlands
| | - V. Hubka
- Department of Botany, Faculty of Science, Charles University, Benátská 2, 128 01 Prague 2, Czech Republic
- Laboratory of Fungal Genetics and Metabolism, Institute of Microbiology of the CAS, v.v.i, Vídeòská 1083, 142 20 Prague 4, Czech Republic
| | - A. Inamdar
- Department of Biotechnology and Microbiology, Vivekanand Arts, Sardar Dalipsingh Commerce and Science College, Aurangabad 431001, Maharashtra, India
| | - T. Iturriaga
- University of Illinois Urbana-Champaign, Illinois Natural History Survey, 1816 South Oak Street, Champaign, Illinois, 61820, USA
- Plant Pathology Herbarium, 334 Plant Science Building, Cornell University, Ithaca, NY 14853 USA
| | - I. Iturrieta-González
- Mycology Unit, Medical School and IISPV, Universitat Rovira i Virgili (URV), Sant Llorenç 21, 43201 Reus, Tarragona, Spain
| | - M. Jadan
- Ruđer Bošković Institute, Bijenička cesta 54, HR-10000 Zagreb, Croatia
| | - N. Jiang
- The Key Laboratory for Silviculture and Conservation of Ministry of Education, Beijing Forestry University, Beijing 100083, China
| | - A. Justo
- Department of Biology, Clark University, 950 Main St, Worcester, 01610, MA, USA
| | - A.V. Kachalkin
- Lomonosov Moscow State University, Moscow, Russia
- All-Russian Collection of Microorganisms, G.K. Skryabin Institute of Biochemistry and Physiology of Microorganisms RAS, Pushchino, Russia
| | - V.I. Kapitonov
- Tobolsk Complex Scientific Station of the Ural Branch of the Russian Academy of Sciences, 626152 Tobolsk, Russia
| | - M. Karadelev
- Institute of Biology, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia
| | - J. Karakehian
- Farlow Herbarium, Harvard University, 22 Divinity Avenue, Cambridge, MA 02138, USA
| | - T. Kasuya
- Department of Biology, Keio University, 4-1-1, Hiyoshi, Kohoku-ku, Yokohama, Kanagawa 223-8521, Japan
| | - I. Kautmanová
- Slovak National Museum-Natural History Museum, vjanaskeho nab. 2, P.O. Box 13, 81006 Bratislava, Slovakia
| | - J. Kruse
- Centre for Crop Health, University of Southern Queensland, Toowoomba 4350, Australia
| | - I. Kušan
- Ruđer Bošković Institute, Bijenička cesta 54, HR-10000 Zagreb, Croatia
| | - T.A. Kuznetsova
- A.N. Severtsov Institute of Ecology and Evolution RAS, Moscow, Russia
| | - M.F. Landell
- Instituto de Ciências Biológicas e da Saúde – ICBS, Universidade Federal de Alagoas, Maceió, Brazil
| | - K.-H. Larsson
- Natural History Museum, P.O. Box 1172 Blindern 0318, University of Oslo, Norway
| | - H.B. Lee
- Environmental Microbiology Lab, Division of Food Technology, Biotechnology & Agrochemistry, College of Agriculture and Life Sciences, Chonnam National University, Korea
| | - D.X. Lima
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - C.R.S. Lira
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - A.R. Machado
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - H. Madrid
- Centro de Genómica y Bioinformática, Facultad de Ciencias, Universidad Mayor, Camino La Pirámide 5750, Huechuraba, Santiago, Chile
| | - O.M.C. Magalhães
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - H. Majerova
- Faculty of Chemical and Food Technology, Biochemistry and Microbiology Department, Slovak University of Technology, Radlinského 9, 81237 Bratislava, Slovakia
| | - E.F. Malysheva
- Komarov Botanical Institute of the Russian Academy of Sciences, Saint Petersburg, Russia
| | - R.R. Mapperson
- Centre for Crop Health, University of Southern Queensland, Toowoomba 4350, Australia
| | | | - M.P. Martín
- Departamento de Micología, Real Jardín Botánico, RJB-CSIC, Plaza de Murillo 2, 28014 Madrid, Spain
| | - A. Martín-Sanz
- Pioneer Hi-Bred International, Inc., Campus Dupont – Pioneer, Ctra. Sevilla-Cazalla km 4.6, 41309 La Rinconada, Spain
| | - N. Matočec
- Ruđer Bošković Institute, Bijenička cesta 54, HR-10000 Zagreb, Croatia
| | - A.R. McTaggart
- Queensland Alliance for Agriculture and Food Innovation, University of Queensland, St Lucia 4069, Australia
| | - J.F. Mello
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - R.F.R. Melo
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - A. Mešić
- Ruđer Bošković Institute, Bijenička cesta 54, HR-10000 Zagreb, Croatia
| | - S.J. Michereff
- Centro de Ciências Agrárias e da Biodiversidade, Universidade Federal do Cariri, Ceará, Brazil
| | - A.N. Miller
- University of Illinois Urbana-Champaign, Illinois Natural History Survey, 1816 South Oak Street, Champaign, Illinois, 61820, USA
| | - A. Minoshima
- Department of Clinical Plant Science, Faculty of Bioscience, Hosei University, 3-7-2 Kajino-cho, Koganei, Tokyo, Japan
| | - L. Molinero-Ruiz
- Department of Crop Protection, Institute for Sustainable Agriculture, CSIC, 14004 Córdoba, Spain
| | - O.V. Morozova
- Komarov Botanical Institute of the Russian Academy of Sciences, Saint Petersburg, Russia
| | - D. Mosoh
- National Centre for Microbial Resource (NCMR), National Centre for Cell Science, S.P. Pune University, Ganeshkhind, Pune 411 007, Maharashtra, India
| | - M. Nabe
- 2-2-1, Sakuragaoka-nakamachi, Nishi-ku, Kobe, Hyogo 651-2226, Japan
| | - R. Naik
- National Centre for Antarctic and Ocean Research, Headland Sada, Vasco-da-Gama-403 804, Goa, India
| | - K. Nara
- Graduate School of Frontier Sciences, The University of Tokyo, Kashiwanoha, Kashiwa, Chiba 277-8563, Japan
| | - S.S. Nascimento
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - R.P. Neves
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - I. Olariaga
- Biology, Geology and Inorganic Chemistry department, Universidad Rey Juan Carlos, C/ Tulipán s/n, 28933 Móstoles, Madrid, Spain
| | - R.L. Oliveira
- Programa de Pós-Graduação em Sistemática e Evolução, Centro de Biociências, Universidade Federal do Rio Grande do Norte, Av. Senador Salgado Filho, 3000, 59072-970, Natal, RN, Brazil
| | - T.G.L. Oliveira
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - T. Ono
- Ogasawara Subtropical Branch of Tokyo Metropolitan Agriculture and Forestry Research Center, Komagari, Chichijima, Ogasawara, Tokyo, Japan
| | - M.E. Ordoñez
- Escuela de Ciencias Biológicas, Pontificia Universidad Católica del Ecuador, Av. 12 de octubre 1076 y Roca, Quito, Ecuador
| | - A. de M. Ottoni
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - L.M. Paiva
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - F. Pancorbo
- Pintores de El Paular 25, 28740 Rascafría, Madrid, Spain
| | - B. Pant
- Central Department of Botany, Tribhuvan University, Nepal
| | - J. Pawłowska
- Department of Molecular Phylogenetics and Evolution, Faculty of Biology, Biological and Chemical Research Centre, University of Warsaw, ul. Zwirki i Wigury 101, 02-089 Warsaw, Poland
| | - S.W. Peterson
- Mycotoxin Prevention and Applied Microbiology Research Unit, Agricultural Research Service, U.S. Department of Agriculture, 1815 North University Street, Peoria, IL 61604, USA
| | - D.B. Raudabaugh
- University of Illinois Urbana-Champaign, Illinois Natural History Survey, 1816 South Oak Street, Champaign, Illinois, 61820, USA
| | - E. Rodríguez-Andrade
- Mycology Unit, Medical School and IISPV, Universitat Rovira i Virgili (URV), Sant Llorenç 21, 43201 Reus, Tarragona, Spain
| | - E. Rubio
- C/ José Cueto 3 – 5ºB, 33401 Avilés, Asturias, Spain
| | - K. Rusevska
- Institute of Biology, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia
| | - A.L.C.M.A. Santiago
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - A.C.S. Santos
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - C. Santos
- Departamento de Ciencias Químicas y Recursos Naturales, BIOREN-UFRO, Universidad de La Frontera, Temuco, Chile
| | - N.A. Sazanova
- Institute of Biological Problems of the North, Far East Branch of the Russian Academy of Sciences, Magadan, Russia
| | - S. Shah
- Central Department of Botany, Tribhuvan University, Nepal
| | - J. Sharma
- Department of Plant and Soil Science, Texas Tech. University, USA
| | - B.D.B. Silva
- Universidade Federal da Bahia, Instituto de Biologia, Departamento de Botânica, 40170115 Ondina, Salvador, BA, Brazil
| | - J.L. Siquier
- Carrer Major, 19, E-07300 Inca (Islas Baleares), Spain
| | - M.S. Sonawane
- National Centre for Microbial Resource (NCMR), National Centre for Cell Science, S.P. Pune University, Ganeshkhind, Pune 411 007, Maharashtra, India
| | - A.M. Stchigel
- Mycology Unit, Medical School and IISPV, Universitat Rovira i Virgili (URV), Sant Llorenç 21, 43201 Reus, Tarragona, Spain
| | - T. Svetasheva
- Biology and Technologies of Living Systems Department, Tula State Lev Tolstoy Pedagogical University, 125 Lenin av., 300026 Tula, Russia
| | - N. Tamakeaw
- Department of Entomology and Plant Pathology, Faculty of Agriculture, Chiang Mai University, Chiang Mai 50200, Thailand
| | - M.T. Telleria
- Departamento de Micología, Real Jardín Botánico, RJB-CSIC, Plaza de Murillo 2, 28014 Madrid, Spain
| | - P.V. Tiago
- Departamento de Micologia, Universidade Federal de Pernambuco, Recife, Brazil
| | - C.M. Tian
- The Key Laboratory for Silviculture and Conservation of Ministry of Education, Beijing Forestry University, Beijing 100083, China
| | - Z. Tkalčec
- Ruđer Bošković Institute, Bijenička cesta 54, HR-10000 Zagreb, Croatia
| | - M.A. Tomashevskaya
- All-Russian Collection of Microorganisms, G.K. Skryabin Institute of Biochemistry and Physiology of Microorganisms RAS, Pushchino, Russia
| | - H.H. Truong
- Department of Clinical Plant Science, Faculty of Bioscience, Hosei University, 3-7-2 Kajino-cho, Koganei, Tokyo, Japan
| | - M.V. Vecherskii
- A.N. Severtsov Institute of Ecology and Evolution RAS, Moscow, Russia
| | - C.M. Visagie
- Department of Biochemistry, Genetics and Microbiology, Forestry and Agricultural Biotechnology Institute (FABI), Faculty of Natural and Agricultural Sciences, University of Pretoria, Private Bag X20, Hatfield 0028, Pretoria, South Africa
- Biosystematics Division, Agricultural Research Council – Plant Health and Protection, P. Bag X134, Queenswood, Pretoria 0121, South Africa
| | - A. Vizzini
- Department of Life Sciences and Systems Biology, University of Turin, Viale P.A. Mattioli 25, 10125, Torino, Italy
| | - N. Yilmaz
- Department of Biochemistry, Genetics and Microbiology, Forestry and Agricultural Biotechnology Institute (FABI), Faculty of Natural and Agricultural Sciences, University of Pretoria, Private Bag X20, Hatfield 0028, Pretoria, South Africa
| | - I.V. Zmitrovich
- Komarov Botanical Institute of the Russian Academy of Sciences, Saint Petersburg, Russia
| | | | - T. Boekhout
- Westerdijk Fungal Biodiversity Institute, P.O. Box 85167, 3508 AD Utrecht, The Netherlands
- Institute of Biodiversity and Ecosystem Dynamics (IBED), University of Amsterdam, Amsterdam, The Netherlands
| | - T. Kehlet
- Natural History Museum of Denmark, Department of Biology, University of Copenhagen, Universitetsparken 15, 2100 Copenhagen E, Denmark
| | - T. Læssøe
- Natural History Museum of Denmark, Department of Biology, University of Copenhagen, Universitetsparken 15, 2100 Copenhagen E, Denmark
| | - J.Z. Groenewald
- Westerdijk Fungal Biodiversity Institute, P.O. Box 85167, 3508 AD Utrecht, The Netherlands
| |
Collapse
|
20
|
Barajas A, Pelaez T, González O, Usall J, Iniesta R, Arteaga M, Jackson C, Baños I, Sánchez B, Dolz M, Obiols JE, Haro JM, Ochoa S, Arranz B, Arteaga M, Asensio R, Autonell J, Baños I, Bañuelos M, Barajas A, Barceló M, Blanc M, Borrás M, Busquets E, Carlson J, Carral V, Castro M, Corbacho C, Coromina M, Dachs I, De Miquel L, Dolz M, Domenech MD, Elias M, Espezel I, Falo E, Fargas A, Foix A, Fusté M, Godrid M, Gómez D, González O, Granell L, Gumà L, Haro JM, Herrera S, Huerta E, Lacasa F, Mas N, Martí L, Martínez R, Matalí J, Miñambres A, Muñoz D, Muñoz V, Nogueroles R, Ochoa S, Ortiz J, Pardo M, Planella M, Pelaez T, Peruzzi S, Rivero S, Rodriguez MJ, Rubio E, Sammut S, Sánchez M, Sánchez B, Serrano E, Solís C, Stephanotto C, Tabuenca P, Teba S, Torres A, Urbano D, Usall J, Vilaplana M, Villalta V. Predictive capacity of prodromal symptoms in first-episode psychosis of recent onset. Early Interv Psychiatry 2019; 13:414-424. [PMID: 29116670 DOI: 10.1111/eip.12498] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Revised: 07/16/2017] [Accepted: 08/20/2017] [Indexed: 11/28/2022]
Abstract
BACKGROUND Both the nature and number of a wide range of prodromal symptoms have been related to the severity and type of psychopathology in the psychotic phase. However, at present there is an incomplete picture focused mainly on the positive pre-psychotic dimension. AIM To characterize the prodromal phase retrospectively, examining the number and nature of prodromal symptoms as well as their relationship with psychopathology at the onset of first-episode psychosis. METHODS Retrospective study of 79 patients experiencing a first-episode psychosis of less than 1 year from the onset of full-blown psychosis. All patients were evaluated with a comprehensive battery of instruments including socio-demographic and clinical questionnaire, IRAOS interview, PANSS, stressful life events scale (PERI) and WAIS/WISC (vocabulary subtest). Bivariate associations and multiple regression analysis were performed. RESULTS Regression models revealed that several prodromal dimensions of IRAOS (delusions, affect, language, behaviour and non-hallucinatory disturbances of perception) predicted the onset of psychosis, with positive (22.4% of the variance) and disorganized (25.6% of the variance) dimensions being the most widely explained. CONCLUSION In addition to attenuated positive symptoms, other symptoms such as affective, behavioural and language disturbances should also be considered in the definitions criteria of at-high-risk people.
Collapse
Affiliation(s)
- Ana Barajas
- Department of Research, Centre d'Higiene Mental Les Corts, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain.,Hospital Sant Joan de Déu de Barcelona, Centro de Investigación Biomédica en Red de Salud Mental, Esplugues de Llobregat, Barcelona, Spain.,Fundació Sant Joan de Déu de Barcelona, Centro de Investigación Biomédica en Red de Salud Mental, Barcelona, Spain.,Department of Clinical and Psychology, School of Psychology, Autonomous University of Barcelona, Cerdanyola del Vallès, Spain
| | - Trinidad Pelaez
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain
| | - Olga González
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain
| | - Judith Usall
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain
| | - Raquel Iniesta
- Fundació Sant Joan de Déu de Barcelona, Centro de Investigación Biomédica en Red de Salud Mental, Barcelona, Spain
| | - Maria Arteaga
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain
| | - Chris Jackson
- Birmingham Early Intervention Service, Birmingham and Solihull Mental Health Foundation Trust, Birmingham, UK
| | - Iris Baños
- Fundació Sant Joan de Déu de Barcelona, Centro de Investigación Biomédica en Red de Salud Mental, Barcelona, Spain
| | - Bernardo Sánchez
- Hospital Sant Joan de Déu de Barcelona, Centro de Investigación Biomédica en Red de Salud Mental, Esplugues de Llobregat, Barcelona, Spain
| | - Montserrat Dolz
- Hospital Sant Joan de Déu de Barcelona, Centro de Investigación Biomédica en Red de Salud Mental, Esplugues de Llobregat, Barcelona, Spain
| | - Jordi E Obiols
- Department of Clinical and Psychology, School of Psychology, Autonomous University of Barcelona, Cerdanyola del Vallès, Spain
| | - Josep M Haro
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain
| | | | - Susana Ochoa
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Rubio E, Borda, K Shirai, A Vivas JG, Garcia V, Peláez P, Gutiérrez M, Barrios V, Ferrero E. Hepatocellular Carcinoma Synchronous Associated to Gastric and Colorrectal Cancer with: an infrequent association. Eur J Surg Oncol 2019. [DOI: 10.1016/j.ejso.2018.10.417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
22
|
Aterido A, Cañete JD, Tornero J, Ferrándiz C, Pinto JA, Gratacós J, Queiró R, Montilla C, Torre-Alonso JC, Pérez-Venegas JJ, Fernández Nebro A, Muñoz-Fernández S, González CM, Roig D, Zarco P, Erra A, Rodríguez J, Castañeda S, Rubio E, Salvador G, Díaz-Torné C, Blanco R, Willisch Domínguez A, Mosquera JA, Vela P, Sánchez-Fernández SA, Corominas H, Ramírez J, de la Cueva P, Fonseca E, Fernández E, Puig L, Dauden E, Sánchez-Carazo JL, López-Estebaranz JL, Moreno D, Vanaclocha F, Herrera E, Blanco F, Fernández-Gutiérrez B, González A, Pérez-García C, Alperi-López M, Olivé Marques A, Martínez-Taboada V, González-Álvaro I, Sanmartí R, Tomás Roura C, García-Montero AC, Bonàs-Guarch S, Mercader JM, Torrents D, Codó L, Gelpí JL, López-Corbeto M, Pluma A, López-Lasanta M, Tortosa R, Palau N, Absher D, Myers R, Marsal S, Julià A. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. Ann Rheum Dis 2018; 78:annrheumdis-2018-214158. [PMID: 30552173 DOI: 10.1136/annrheumdis-2018-214158] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2018] [Revised: 11/16/2018] [Accepted: 11/16/2018] [Indexed: 12/31/2022]
Abstract
OBJECTIVE Psoriatic arthritis (PsA) is a chronic inflammatory arthritis affecting up to 30% of patients with psoriasis (Ps). To date, most of the known risk loci for PsA are shared with Ps, and identifying disease-specific variation has proven very challenging. The objective of the present study was to identify genetic variation specific for PsA. METHODS We performed a genome-wide association study in a cohort of 835 patients with PsA and 1558 controls from Spain. Genetic association was tested at the single marker level and at the pathway level. Meta-analysis was performed with a case-control cohort of 2847 individuals from North America. To confirm the specificity of the genetic associations with PsA, we tested the associated variation using a purely cutaneous psoriasis cohort (PsC, n=614) and a rheumatoid arthritis cohort (RA, n=1191). Using network and drug-repurposing analyses, we further investigated the potential of the PsA-specific associations to guide the development of new drugs in PsA. RESULTS We identified a new PsA risk single-nucleotide polymorphism at B3GNT2 locus (p=1.10e-08). At the pathway level, we found 14 genetic pathways significantly associated with PsA (pFDR<0.05). From these, the glycosaminoglycan (GAG) metabolism pathway was confirmed to be disease-specific after comparing the PsA cohort with the cohorts of patients with PsC and RA. Finally, we identified candidate drug targets in the GAG metabolism pathway as well as new PsA indications for approved drugs. CONCLUSION These findings provide insights into the biological mechanisms that are specific for PsA and could contribute to develop more effective therapies.
Collapse
Affiliation(s)
- Adrià Aterido
- Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.,Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
| | - Juan D Cañete
- Rheumatology Department, Hospital Clínic de Barcelona and IDIBAPS, Barcelona, Spain
| | - Jesús Tornero
- Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain
| | - Carlos Ferrándiz
- Dermatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | - José Antonio Pinto
- Rheumatology Department, Complejo Hospitalario Juan Canalejo, A Coruña, Spain
| | - Jordi Gratacós
- Rheumatology Department, Hospital Parc Taulí, Sabadell, Spain
| | - Rubén Queiró
- Rheumatology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - Carlos Montilla
- Rheumatology Department, Hospital Virgen de la Vega, Salamanca, Spain
| | | | | | - Antonio Fernández Nebro
- Rheumatology Department, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - Santiago Muñoz-Fernández
- Rheumatology Department, Hospital Universitario Infanta Sofía, Universidad Europea, Madrid, Spain
| | - Carlos M González
- Rheumatology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain
| | - Daniel Roig
- Rheumatology Department, Hospital Moisès Broggi, Barcelona, Spain
| | - Pedro Zarco
- Rheumatology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - Alba Erra
- Rheumatology Department, Hospital Sant Rafael, Barcelona, Spain
| | - Jesús Rodríguez
- Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain
| | - Santos Castañeda
- Rheumatology Department, Hospital Universitario La Princesa, IIS La Princesa, Madrid, Spain
| | - Esteban Rubio
- Rheumatology Department, Centro de Salud Virgen de los Reyes, Sevilla, Spain
| | - Georgina Salvador
- Rheumatology Department, Hospital Universitario Mútua de Terrassa, Terrassa, Spain
| | - Cesar Díaz-Torné
- Rheumatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Ricardo Blanco
- Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | | | - José Antonio Mosquera
- Rheumatology Department, Complejo Hospitalario Hospital Provincial de Pontevedra, Pontevedra, Spain
| | - Paloma Vela
- Rheumatology Department, Hospital General Universitario de Alicante, Alicante, Spain
| | | | - Héctor Corominas
- Rheumatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.,Rheumatology Department, Hospital Dos de Maig, Barcelona, Spain
| | - Julio Ramírez
- Rheumatology Department, Hospital Clínic de Barcelona and IDIBAPS, Barcelona, Spain
| | - Pablo de la Cueva
- Dermatology Department, Hospital Universitario Infanta Leonor, Madrid, Spain
| | - Eduardo Fonseca
- Dermatology Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain
| | - Emilia Fernández
- Dermatology Department, Hospital Universitario de Salamanca, Salamanca, Spain
| | - Lluis Puig
- Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Esteban Dauden
- Dermatology Department, Hospital Universitario La Princesa, IIS La Princesa, Madrid, Spain
| | | | | | - David Moreno
- Dermatology Department, Hospital Virgen Macarena, Sevilla, Spain
| | | | - Enrique Herrera
- Dermatology Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain
| | - Francisco Blanco
- Rheumatology Department, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain
| | | | - Antonio González
- Instituto de Investigación Sanitaria Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
| | | | | | | | | | | | - Raimon Sanmartí
- Rheumatology Department, Hospital Clínic de Barcelona and IDIBAPS, Barcelona, Spain
| | | | | | - Sílvia Bonàs-Guarch
- Barcelona Supercomputing Centre (BSC), Joint BSC-CRG-IRB Research Program in Computational Biology, Barcelona, Spain
| | - Josep Maria Mercader
- Barcelona Supercomputing Centre (BSC), Joint BSC-CRG-IRB Research Program in Computational Biology, Barcelona, Spain
| | - David Torrents
- Barcelona Supercomputing Centre (BSC), Joint BSC-CRG-IRB Research Program in Computational Biology, Barcelona, Spain.,Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
| | - Laia Codó
- Life Sciences Department, Barcelona Supercomputing Centre, Barcelona, Spain
| | - Josep Lluís Gelpí
- Life Sciences Department, Barcelona Supercomputing Centre, Barcelona, Spain
| | | | - Andrea Pluma
- Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain
| | - Maria López-Lasanta
- Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain
| | - Raül Tortosa
- Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain
| | - Nuria Palau
- Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain
| | - Devin Absher
- HudsonAlpha Institute for Biotechnology, Huntsville, Alabama, USA
| | - Richard Myers
- HudsonAlpha Institute for Biotechnology, Huntsville, Alabama, USA
| | - Sara Marsal
- Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain
| | - Antonio Julià
- Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain
| |
Collapse
|
23
|
Lozano Galan J, Rubio E, Solé J. EP-1648: Palliative hipofractionated radiotherapy in non operable rectal cancer: preliminary results. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31957-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
24
|
Lander B, Alvarado M, Alvarez IC, Armas E, Chique-Alfonzo G, Hernandez F, Labarca R, Leon R, Molina O, Monasterios I, Ramirez CI, Rubio E, Torres B, Viso-Barroso R, Simmonds Z, Soto A. [Venezuelan consensus guidelines on the use of magnetic resonance in diagnosis and follow up of patients with multiple sclerosis]. Rev Neurol 2017; 65:117-126. [PMID: 28699154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
INTRODUCTION The clinical use of magnetic resonance (MR) in patients with multiple sclerosis (MS) has advanced markedly over the past few years. Several groups around the world have developed consensus guidelines about the role of MR in MS at diagnosis and during follow up. However, in some regions is difficult to extrapolate the recommendations. AIM To provide recommendations for the implementation of MR in MS patients at diagnosis and follow up in Venezuela. DEVELOPMENT A group of experts from Venezuela that included neurologists and radiologists, by using the online surveys methodology as well as face to face meetings developed the intended consensus for the use of MR during the diagnosis and follow up of MS patients in Venezuela. Seventeen recommendations were established based on published evidence and the expert opinion. Recommendations focused on the role of conventional MR techniques and brain atrophy measurement in MS patients both at diagnosis and during follow-up. CONCLUSIONS The recommendations of this consensus guidelines attempts to optimize the health care and management of patients with MS in Venezuela.
Collapse
Affiliation(s)
- B Lander
- Universidad Central de Caracas, Caracas, Venezuela
| | - M Alvarado
- Universidad Central de Caracas, Caracas, Venezuela
| | | | - E Armas
- Universidad Central de Caracas, Caracas, Venezuela
| | | | - F Hernandez
- Hospital Universitario de Maracaibo, Maracaibo, Venezuela
| | - R Labarca
- Hospital Universitario de Maracaibo, Maracaibo, Venezuela
| | - R Leon
- Instituto de Salud del Estado Carabobo, Valencia, Venezuela
| | - O Molina
- Hospital Universitario de Maracaibo, Maracaibo, Venezuela
| | | | - C I Ramirez
- Instituto Autonomo Hospital Universitario de Los Andes (IAHULA), Merida, Venezuela
| | - E Rubio
- Hospital Dr. Domingo Luciani, Caracas, Venezuela
| | - B Torres
- Hospital Central de Maracay, Maracay, Venezuela
| | | | - Z Simmonds
- Hospital Universitario Dr. Luis Razetti, Barcelona, Venezuela
| | - A Soto
- Centro Medico Docente La Trinidad, Caracas, Venezuela
| |
Collapse
|
25
|
Ortillés Á, Belloc J, Rubio E, Fernández MT, Benito M, Cristóbal JÁ, Calvo B, Goñi P. In-vitro development of an effective treatment for Acanthamoeba keratitis. Int J Antimicrob Agents 2017; 50:325-333. [PMID: 28709990 DOI: 10.1016/j.ijantimicag.2017.03.033] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2016] [Revised: 03/07/2017] [Accepted: 03/11/2017] [Indexed: 10/19/2022]
Abstract
The aim of this study was to develop an in-vitro topical treatment for Acanthamoeba keratitis (AK) effective against cysts and trophozoites. Qualitative assays were performed with voriconazole, chlorhexidine, propamidine, cellulase, tobramycin, ciprofloxacin and paromomycin as monotherapy and various combinations. Riboflavin with ultraviolet-A (R + UV-A) as monotherapy or combined with voriconazole and moxifloxacin was also tested. Quantitative assays to assess cyst viability after treatment were performed for the chemicals that showed the highest activity in the qualitative assays. Paromomycin and propamidine did not show antiamoebic activity. Regardless of the total dose, no amoebicidal effect was observed for R + UV-A. Tobramycin, ciprofloxacin, voriconazole, chlorhexidine and cellulase were selected for quantitative assays because they appeared to cause greater damage to the structure of amoebae. Chlorhexidine and ciprofloxacin were the most active against Acanthamoeba spp. as monotherapy. Among the combinations evaluated, ciprofloxacin-voriconazole-chlorhexidine showed the greatest amoebicidal activity, with severe damage of the cellular membrane and an important decrease in cell concentration. In summary, ciprofloxacin as monotherapy and in combination with voriconazole and chlorhexidine has been classified as promising treatment. Additional in-vivo studies in animal models and clinical trials in patients with AK should be considered to confirm the efficacy of ciprofloxacin.
Collapse
Affiliation(s)
- Á Ortillés
- Aragón Institute of Engineering Research, University of Zaragoza, Zaragoza, Spain; Department of Animal Pathology, University of Zaragoza, Zaragoza, Spain.
| | - J Belloc
- Department of Microbiology, Preventive Medicine and Public Health, University of Zaragoza, Zaragoza, Spain
| | - E Rubio
- Department of Microbiology, Preventive Medicine and Public Health, University of Zaragoza, Zaragoza, Spain
| | - M T Fernández
- Department of Physiatry and Nursery, University of Zaragoza, Zaragoza, Spain
| | - M Benito
- Department of Microbiology, Preventive Medicine and Public Health, University of Zaragoza, Zaragoza, Spain
| | - J Á Cristóbal
- Department of Ophthalmology, 'Lozano Blesa' University Clinic Hospital, Zaragoza, Spain
| | - B Calvo
- Aragón Institute of Engineering Research, University of Zaragoza, Zaragoza, Spain; Bioengineering, Biomaterials and Nanomedicine Online Biomedical Research Centre, Madrid, Spain
| | - P Goñi
- Department of Microbiology, Preventive Medicine and Public Health, University of Zaragoza, Zaragoza, Spain
| |
Collapse
|
26
|
López-Mejías R, Carmona FD, Castañeda S, Genre F, Remuzgo-Martínez S, Sevilla-Perez B, Ortego-Centeno N, Llorca J, Ubilla B, Mijares V, Pina T, Miranda-Filloy JA, Navas Parejo A, de Argila D, Aragües M, Rubio E, Luque ML, Blanco-Madrigal JM, Galíndez-Aguirregoikoa E, Jayne D, Blanco R, Martín J, González-Gay MA. A genome-wide association study suggests the HLA Class II region as the major susceptibility locus for IgA vasculitis. Sci Rep 2017; 7:5088. [PMID: 28698626 PMCID: PMC5506002 DOI: 10.1038/s41598-017-03915-2] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2017] [Accepted: 05/05/2017] [Indexed: 12/13/2022] Open
Abstract
The genetic component of Immunoglobulin-A (IgA) vasculitis is still far to be elucidated. To increase the current knowledge on the genetic component of this vasculitis we performed the first genome-wide association study (GWAS) on this condition. 308 IgA vasculitis patients and 1,018 healthy controls from Spain were genotyped by Illumina HumanCore BeadChips. Imputation of GWAS data was performed using the 1000 Genomes Project Phase III dataset as reference panel. After quality control filters and GWAS imputation, 285 patients and 1,006 controls remained in the datasets and were included in further analysis. Additionally, the human leukocyte antigen (HLA) region was comprehensively studied by imputing classical alleles and polymorphic amino acid positions. A linkage disequilibrium block of polymorphisms located in the HLA class II region surpassed the genome-wide level of significance (OR = 0.56, 95% CI = 0.46–0.68). Although no polymorphic amino acid positions were associated at the genome-wide level of significance, P-values of potential relevance were observed for the positions 13 and 11 of HLA-DRB1 (P = 6.67E-05, P = 1.88E-05, respectively). Outside the HLA, potential associations were detected, but none of them were close to the statistical significance. In conclusion, our study suggests that IgA vasculitis is an archetypal HLA class II disease.
Collapse
Affiliation(s)
- Raquel López-Mejías
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
| | - F David Carmona
- Instituto de Parasitología y Biomedicina 'López-Neyra', CSIC, PTS Granada, Granada, Spain.,Departamento de Genética e Instituto de Biotecnología, Universidad de Granada, Granada, Spain
| | - Santos Castañeda
- Rheumatology Department, Hospital Universitario La Princesa, IIS-IPrincesa, Madrid, Spain
| | - Fernanda Genre
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - Sara Remuzgo-Martínez
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
| | | | | | - Javier Llorca
- Epidemiology and Computational Biology Department, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain
| | - Begoña Ubilla
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - Verónica Mijares
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - Trinitario Pina
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
| | | | | | - Diego de Argila
- Dermatology Department, Hospital Universitario La Princesa, IIS-IPrincesa, Madrid, Spain
| | - Maximiliano Aragües
- Dermatology Department, Hospital Universitario La Princesa, IIS-IPrincesa, Madrid, Spain
| | - Esteban Rubio
- Rheumatology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - Manuel León Luque
- Rheumatology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | | | | | - David Jayne
- Department of Medicine, University of Cambridge, Cambridge, UK
| | - Ricardo Blanco
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - Javier Martín
- Instituto de Parasitología y Biomedicina 'López-Neyra', CSIC, PTS Granada, Granada, Spain
| | - Miguel A González-Gay
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.,School of Medicine, University of Cantabria, Santander, Spain.,Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| |
Collapse
|
27
|
Martínez-García E, Dadi T, Rubio E, García-Morote FA, Andrés-Abellán M, López-Serrano FR. Aboveground autotrophic respiration in a Spanish black pine forest: Comparison of scaling methods to improve component partitioning. Sci Total Environ 2017; 580:1505-1517. [PMID: 28040216 DOI: 10.1016/j.scitotenv.2016.12.136] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/10/2016] [Revised: 12/20/2016] [Accepted: 12/20/2016] [Indexed: 06/06/2023]
Abstract
Total wood CO2 efflux (Rw) varies vertically within individual trees, and leaves experience large variations in foliar respiration (Rf) rates over their life spans and during daily periods. Therefore, accurate sampling approaches are required to improve aboveground autotrophic respiration (RAa) estimations in stand-scale carbon cycling studies. We scaled-up Rw (comprising stem and branch CO2 efflux; ES and EB, respectively) and Rf from biometric and flux-chamber measurements taken between 2011 and 2013 in a Spanish black pine (Pinus nigra Arn. ssp. salzmannii) forest at an unburnt (UB) site and a low burn-severity (LS) site. We measured seasonal ES at breast height (1.30m) on 9 trees at each site, which was also vertically examined on 5 of those trees. We also measured seasonal Rf in current- and previous-year needles on 3 trees at each site, and quantified Rf variations in darkness and light. Finally, we compared complex and simple scale-up methods which did or did not account for the vertical variation in Rw and the effects of leaf ageing and light inhibition on Rf, respectively. The simple methods underestimated the annual stand-level stem, branch, and total wood respiration ≈35%, 55%, and 41%, respectively, and overestimated annual stand-level whole-canopy foliage respiration ≈43% at both sites. Both methods provided similar annual stand-level RAa estimates, although the complex methods improved estimations of the relative contribution of RAa components. Thus, based on the complex methods the mean annual RAa at the stand-level was 4.53±0.25 and 4.45±0.12MgCha-1year-1 at the UB and LS sites, respectively. Our data also confirmed that the low-severity fire did not alter the RAa rates. Collectively, this study reveals that complex approaches, applicable in other forest ecosystems, enhance the accuracy of partitioning RAa sources by reducing the error in scaling-up in chamber-based measurements.
Collapse
Affiliation(s)
- E Martínez-García
- Department of Science and Agroforestry Technology and Genetics, Higher Technical School of Agricultural and Forestry Engineering, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain; Environmental Department, Renewable Energy Research Institute, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain.
| | - T Dadi
- Department of Science and Agroforestry Technology and Genetics, Higher Technical School of Agricultural and Forestry Engineering, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain; Environmental Department, Renewable Energy Research Institute, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain
| | - E Rubio
- Department of Applied Physics, School of Industrial Engineering, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain; Environmental Department, Renewable Energy Research Institute, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain
| | - F A García-Morote
- Department of Science and Agroforestry Technology and Genetics, Higher Technical School of Agricultural and Forestry Engineering, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain; Environmental Department, Renewable Energy Research Institute, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain
| | - M Andrés-Abellán
- Department of Science and Agroforestry Technology and Genetics, Higher Technical School of Agricultural and Forestry Engineering, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain; Environmental Department, Renewable Energy Research Institute, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain
| | - F R López-Serrano
- Department of Science and Agroforestry Technology and Genetics, Higher Technical School of Agricultural and Forestry Engineering, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain; Environmental Department, Renewable Energy Research Institute, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain
| |
Collapse
|
28
|
López-Serrano FR, Rubio E, Dadi T, Moya D, Andrés-Abellán M, García-Morote FA, Miettinen H, Martínez-García E. Influences of recovery from wildfire and thinning on soil respiration of a Mediterranean mixed forest. Sci Total Environ 2016; 573:1217-1231. [PMID: 27179619 DOI: 10.1016/j.scitotenv.2016.03.242] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/29/2015] [Revised: 03/30/2016] [Accepted: 03/31/2016] [Indexed: 06/05/2023]
Abstract
The ecosystem recovery after wildfire and thinning practices are both key processes that have great potential to influence fluxes and storage of carbon within Mediterranean semiarid ecosystems. In this study, started 7years after a wildfire, soil respiration (SR) patterns measured from 2008 to 2010 were compared between an unmanaged-undisturbed mature forest stand (UB site) and a naturally regenerated post-wildfire stand (B site) in a Mediterranean mixed forest in Spain. The disturbed stand included a control zone (unthinned forest, BUT site) and a thinned zone (BT site). Our results indicated that SR was lower at naturally regenerated after fire sites (BUT and BT) than at unburnt one. Soil under the canopy layer of pine and oak trees exhibited higher SR rates than bare or herbaceous layer soils, regardless of the site. The effect of thinning was only manifest, with a significant increase of SR, during the 1st year after thinning practices. SR showed a clear soil temperature-dependent seasonal pattern, which was strongly modulated by soil water content (SWC), especially in summer. Site-specific polynomial regression models were defined to describe SR responses, being mainly controlled by both soil temperature (Ts) and SWC at UB site, or Ts at burnt sites. The sensitivity of SR rate to Ts variations (Q10) ranged between 0.20 and 6.89, with mean annual values varying between 0.92 and 1.35. Q10 values were higher at BT than at UB-BUT sites. The results revealed a significant, non-linear dependence, of Q10 on both Ts and SWC at UB site, and on Ts at both burnt sites. This study contributes to (i) improve the understanding of how natural recovery and management practices affect soil respiration in a Mediterranean forest during their early stages after fire disturbance and (ii) highlight the importance of Q10 values <1 which emphasizes drought stress effect on SR temperature sensitivity.
Collapse
Affiliation(s)
- F R López-Serrano
- Department of Science and Agroforestry Technology and Genetics, Higher Technical School of Agricultural and Forestry Engineering, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain; Environmental Department, Renewable Energy Research Institute, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain
| | - E Rubio
- Department of Applied Physics, School of Industrial Engineering, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain.
| | - T Dadi
- Department of Science and Agroforestry Technology and Genetics, Higher Technical School of Agricultural and Forestry Engineering, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain; Environmental Department, Renewable Energy Research Institute, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain
| | - D Moya
- Department of Plant Production, Higher Technical School of Agricultural and Forestry Engineering, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain
| | - M Andrés-Abellán
- Department of Science and Agroforestry Technology and Genetics, Higher Technical School of Agricultural and Forestry Engineering, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain; Environmental Department, Renewable Energy Research Institute, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain
| | - F A García-Morote
- Department of Science and Agroforestry Technology and Genetics, Higher Technical School of Agricultural and Forestry Engineering, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain; Environmental Department, Renewable Energy Research Institute, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain
| | - H Miettinen
- Department of Science and Agroforestry Technology and Genetics, Higher Technical School of Agricultural and Forestry Engineering, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain; Environmental Department, Renewable Energy Research Institute, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain
| | - E Martínez-García
- Department of Science and Agroforestry Technology and Genetics, Higher Technical School of Agricultural and Forestry Engineering, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain; Environmental Department, Renewable Energy Research Institute, University of Castilla-La Mancha, Campus Universitario s/n, CP 02071 Albacete, Spain
| |
Collapse
|
29
|
Lafuente O, Sánchez-Sobrino B, Pérez M, López-Sánchez P, Janeiro D, Rubio E, Huerta A, Marques M, Llópez-Carratala M, Rubio J, Portolés J. Midterm Results of Renal Transplantation From Controlled Cardiac Death Donors Are Similar to Those From Brain Death Donors. Transplant Proc 2016; 48:2862-2866. [DOI: 10.1016/j.transproceed.2016.08.039] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2016] [Accepted: 08/22/2016] [Indexed: 10/20/2022]
|
30
|
Rubio E, Nuño J, Brandariz L, Domínguez I, Bernal J, Vivas A, Alonso O, González S, Pelaez P, Perea J, Garcia Borda J, Ferrero E. 465. Surgical aggressive treatment of primary and liver metastases of neuroendocrine tumors. Eur J Surg Oncol 2016. [DOI: 10.1016/j.ejso.2016.06.293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
31
|
Martínez Pérez R, Rubio E, Fernández Alba M, Hernández B, Menor R, Povedano J. AB0972 Utility of The Ultrasound for The Evaluation of Activity in Patients with Rheumatoid Arthritis in Remission or Low Clinical Activity in Treatment with Biological in Optimization Phase: Table 1. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4766] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
32
|
Martínez López JA, García Vivar ML, Cáliz R, Freire M, Galindo M, Hernández MV, López Longo FJ, Martínez Taboada V, Pego Reigosa JM, Rubio E, Trujillo E, Vela-Casasempere P. Recommendations for the evaluation and management of patients with rheumatic autoimmune and inflammatory diseases during the reproductive age, pregnancy, postpartum and breastfeeding. ACTA ACUST UNITED AC 2016; 13:264-281. [PMID: 27321859 DOI: 10.1016/j.reuma.2016.05.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2016] [Revised: 05/02/2016] [Accepted: 05/07/2016] [Indexed: 01/18/2023]
Abstract
OBJECTIVE To develop recommendations on the evaluation and management of patients with rheumatic autoimmune and inflammatory diseases during the reproductive age, pregnancy, post-partum and breastfeeding based on the best evidence and experience. METHODS Recommendations were generated using nominal group and Delphi techniques. An expert panel of 12 rheumatologists was established. A systematic literature review and a narrative review (websites, clinical guidelines and other relevant documentation) were performed and presented to the panel in its 1st meeting to be discussed and to help define recommendations. A first draft of recommendations was generated and circulated for comments and wording refinement. A national survey analyzing different aspects of this topic was undertaken separately, followed by a Delphi process (2 rounds). Agreement with each recommendation was ranked on a scale of 1 (total disagreement) to 10 (total agreement), and was considered to be achieved if at least 70% voted≥7. The level of evidence and grade of recommendation were assessed using the Oxford Centre for Evidence-based Medicine Levels of Evidence. RESULTS A total of 14 recommendations were generated for the preconception period (oral and hormonal contraception, reproductive techniques), pregnancy (planning, treatment and follow-up), and breastfeeding (treatment and follow-up). High-risk situations such as lupus or antiphospholipid syndrome were included. A consensus>90% was reached for all but one recommendation. CONCLUSIONS These recommendations are intended to provide rheumatologists, patients, families and other stakeholders with a consensus on the evaluation and management of patients with autoimmune and inflammatory diseases during the reproductive age, pregnancy, postpartum and breastfeeding.
Collapse
Affiliation(s)
| | - M Luz García Vivar
- Servicio de Reumatología, Hospital Universitario Basurto, Bilbao, España
| | - Rafael Cáliz
- Unidad de Gestión de Reumatología, Complejo Hospitalario Universitario de Granada, Granada, España
| | - Mercedes Freire
- Servicio de Reumatología, Complexo hospitalario Universitario A Coruña (CHUAC), A Coruña, España
| | - María Galindo
- Servicio de Reumatología, Hospital Universitario 12 de Octubre, Madrid, España
| | | | | | - Víctor Martínez Taboada
- Servicio de Reumatología, Hospital Universitario Marqués de Valdecilla, Santander, España; Facultad de Medicina, Universidad de Cantabria, Santander, España
| | - Jose María Pego Reigosa
- Servicio de Reumatología, Hospital Meixoeiro-Complexo Hospitalario Universitario de Vigo, Vigo, España
| | - Esteban Rubio
- Servicio de Reumatología, Hospital Universitario Virgen del Rocío, Sevilla, España
| | - Elisa Trujillo
- Servicio de Reumatología, Hospital Universitario de Canarias, Santa Cruz de Tenerife, España
| | | |
Collapse
|
33
|
Ruiz A, Rubio E, Porras I, Garcia-Morillo S, Povedano J. AB0902 Genetic Characterization of Hereditary Periodic Fever Syndromes: A Retrospective Cohort of 25 Patients. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.5124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
34
|
Martínez-Lόpez J, García Vivar M, Caliz R, Loza E, Freire M, Galindo M, Hernández M, Lόpez Longo F, Martínez Taboada V, Pego Reigosa J, Rubio E, Trujillo E, Vela-Casasempere P. SAT0591 Consensus Statement for The Evaluation and Management of Patients with Autoimmune and Inflammatory Diseases during Fertility, Pregnancy, Post-Partum and Breastfeeding. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.5257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
35
|
Hernández-Cruz B, Leόn Rubio P, Rubio E, Lisbona M, Fernández M, Valenzuela M, Decán D, Ojeda García C, Leόn M, Ruiz A, Povedano Gόmez J. AB0773 The Treatment with Denosumab plus Biologic Dmards in Patients with Rheumatic Chronic Diseases Showed Efficacy and Safety. A Case Series. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
36
|
Fernández-Díaz C, Loricera J, Blanco R, Hernández J, Castañeda S, Humbría A, Melchor S, Collado P, Calvo-Catalá J, Rubio E, Rosas J, Ariza R, Rúa-Figueroa Í, Peirό E, Calvo-Río V, González-Vela C, González-Gay M. SAT0331 itnfα Agents in Refractory Non-Infectious Aortitis: Study on 19 Patients. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4765] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
37
|
Rubio E, Ruiz A, Lόpez J, Lόpez-Chozas J, Bermudez L, Aguilera C, Povedano J. AB0310 Prospective Study of 78 Patients Treated with Infliximab Biosimilar Remsima®. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.5688] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
38
|
Cañete J, Pinto J, Gratacos J, Queiro R, Montilla C, Torre-Alonso J, Perez-Venegas J, Fernández Nebro A, Muñoz S, Gonzalez C, Roig D, Zarco P, Erra A, Rodriguez J, Castañeda S, Rubio E, Salvador G, Diaz C, Blanco R, Willisch A, Mosquera J, Vela P, Tornero J, Sanchez S, Corominas H, Ramirez J, Lopez-Lasanta M, Lόpez-Corbeto M, Tortosa R, Julià A, Marsal S. AB0007 Genome-Wide Association Study of Clinical Phenotypes in Psoriatic Arthritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
39
|
López-Mejías R, Genre F, Remuzgo-Martínez S, Sevilla Pérez B, Castañeda S, Llorca J, Ortego-Centeno N, Ubilla B, Mijares V, Pina T, Calvo-Río V, Miranda-Filloy JA, Navas Parejo A, Argila D, Sánchez-Pérez J, Rubio E, Luque ML, Blanco-Madrigal JM, Galíndez-Aguirregoikoa E, Martín J, Blanco R, González-Gay MA. Interleukin 1 beta (IL1ß) rs16944 genetic variant as a genetic marker of severe renal manifestations and renal sequelae in Henoch-Schönlein purpura. Clin Exp Rheumatol 2016; 34:S84-S88. [PMID: 26842496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2015] [Accepted: 01/18/2016] [Indexed: 06/05/2023]
Abstract
OBJECTIVES Data from a small series suggested that the Interleukin 1 beta (IL1ß) rs16944 polymorphism may be associated with severe renal involvement and persistent renal damage (renal sequelae) in Henoch-Schönlein purpura (HSP). To confirm this association, we assessed the largest cohort of Caucasian HSP patients ever considered for genetic studies. METHODS 338 Spanish HSP patients and 635 sex and ethnically matched controls were recruited in this study. All patients were required to have had at least 6 months' follow-up. Patients and controls were genotyped for IL1β rs16944 by TaqMan genotyping assay. RESULTS No differences between IL1β rs16944 genotype or allele frequencies were found either in the case/control study or when HSP patients were stratified according to the age at disease onset, presence of nephritis or gastrointestinal manifestations. Nevertheless, 4 (25%) of the 16 HSP patients who developed severe renal manifestations carried the TT genotype versus 29 (9%) of 322 who did not develop this complication (p=0.01, OR=5.48, 95% CI: 1.01-28.10). Accordingly, patients carrying the mutant T allele had an increased risk of developing severe nephropathy (p=0.016, OR=2.35, 95% CI: 1.09-5.07). Additionally, a significant increase of the TT genotype was observed in patients with persistent renal damage when compared with those patients without this complication (25% versus 8.6%, respectively; p=0.0035, OR=4.90, 95% CI: 1.26- 18.51). Moreover, renal sequelae were more common in patients carrying the mutant T allele (p=0.0076, OR=2.20, 95% CI: 1.17-4.14). CONCLUSIONS Our results support that the IL1ß rs16944 polymorphism may be a potential marker of severe renal manifestations and renal sequelae in HSP.
Collapse
Affiliation(s)
- Raquel López-Mejías
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain
| | - Fernanda Genre
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain
| | - Sara Remuzgo-Martínez
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain
| | | | - Santos Castañeda
- Rheumatology Department, Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain
| | - Javier Llorca
- Epidemiology and Computational Biology Department, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain
| | | | - Begoña Ubilla
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain
| | - Verónica Mijares
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain
| | - Trinitario Pina
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain
| | - Vanesa Calvo-Río
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain
| | | | | | - Diego Argila
- Dermatology Department, Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain
| | - Javier Sánchez-Pérez
- Dermatology Department, Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain
| | - Esteban Rubio
- Rheumatology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - Manuel León Luque
- Rheumatology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | | | | | - Javier Martín
- Institute of Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain
| | - Ricardo Blanco
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain
| | - Miguel A González-Gay
- Epidemiology, Genetics & Atherosclerosis Res.Group, Systemic Inflammatory Diseases, IDIVAL; School of Medicine, Univ.of Cantabria, Santander, Spain; and Cardiovascular Pathophysiology & Genomics Research, Univ.of Witwatersrand, Johannesburg, South Africa
| |
Collapse
|
40
|
Zboromyrska Y, Rubio E, Alejo I, Vergara A, Mons A, Campo I, Bosch J, Marco F, Vila J. Development of a new protocol for rapid bacterial identification and susceptibility testing directly from urine samples. Clin Microbiol Infect 2016; 22:561.e1-6. [PMID: 26899829 DOI: 10.1016/j.cmi.2016.01.025] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2015] [Revised: 11/23/2015] [Accepted: 01/28/2016] [Indexed: 01/21/2023]
Abstract
The current gold standard method for the diagnosis of urinary tract infections (UTI) is urine culture that requires 18-48 h for the identification of the causative microorganisms and an additional 24 h until the results of antimicrobial susceptibility testing (AST) are available. The aim of this study was to shorten the time of urine sample processing by a combination of flow cytometry for screening and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) for bacterial identification followed by AST directly from urine. The study was divided into two parts. During the first part, 675 urine samples were processed by a flow cytometry device and a cut-off value of bacterial count was determined to select samples for direct identification by MALDI-TOF-MS at ≥5 × 10(6) bacteria/mL. During the second part, 163 of 1029 processed samples reached the cut-off value. The sample preparation protocol for direct identification included two centrifugation and two washing steps. Direct AST was performed by the disc diffusion method if a reliable direct identification was obtained. Direct MALDI-TOF-MS identification was performed in 140 urine samples; 125 of the samples were positive by urine culture, 12 were contaminated and 3 were negative. Reliable direct identification was obtained in 108 (86.4%) of the 125 positive samples. AST was performed in 102 identified samples, and the results were fully concordant with the routine method among 83 monomicrobial infections. In conclusion, the turnaround time of the protocol described to diagnose UTI was about 1 h for microbial identification and 18-24 h for AST.
Collapse
Affiliation(s)
- Y Zboromyrska
- Department of Clinical Microbiology, Hospital Clínic, School of Medicine, University of Barcelona, Barcelona, Spain; ISGlobal, Barcelona Centre for International Health Research (CRESIB), Hospital Clínic, University of Barcelona, Barcelona, Spain
| | - E Rubio
- Department of Clinical Microbiology, Hospital Clínic, School of Medicine, University of Barcelona, Barcelona, Spain
| | - I Alejo
- Department of Clinical Microbiology, Hospital Clínic, School of Medicine, University of Barcelona, Barcelona, Spain
| | - A Vergara
- Department of Clinical Microbiology, Hospital Clínic, School of Medicine, University of Barcelona, Barcelona, Spain
| | - A Mons
- Department of Clinical Microbiology, Hospital Clínic, School of Medicine, University of Barcelona, Barcelona, Spain
| | - I Campo
- Department of Clinical Microbiology, Hospital Clínic, School of Medicine, University of Barcelona, Barcelona, Spain
| | - J Bosch
- Department of Clinical Microbiology, Hospital Clínic, School of Medicine, University of Barcelona, Barcelona, Spain; ISGlobal, Barcelona Centre for International Health Research (CRESIB), Hospital Clínic, University of Barcelona, Barcelona, Spain
| | - F Marco
- Department of Clinical Microbiology, Hospital Clínic, School of Medicine, University of Barcelona, Barcelona, Spain; ISGlobal, Barcelona Centre for International Health Research (CRESIB), Hospital Clínic, University of Barcelona, Barcelona, Spain
| | - J Vila
- Department of Clinical Microbiology, Hospital Clínic, School of Medicine, University of Barcelona, Barcelona, Spain; ISGlobal, Barcelona Centre for International Health Research (CRESIB), Hospital Clínic, University of Barcelona, Barcelona, Spain.
| |
Collapse
|
41
|
Munoz JE, Bermudez I Badia S, Rubio E, Cameirao MS. Visualization of multivariate physiological data for cardiorespiratory fitness assessment through ECG (R-peak) analysis. Annu Int Conf IEEE Eng Med Biol Soc 2016; 2015:390-3. [PMID: 26736281 DOI: 10.1109/embc.2015.7318381] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
The recent rise and popularization of wearable and ubiquitous fitness sensors has increased our ability to generate large amounts of multivariate data for cardiorespiratory fitness (CRF) assessment. Consequently, there is a need to find new methods to visualize and interpret CRF data without overwhelming users. Current visualizations of CRF data are mainly tabular or in the form of stacked univariate plots. Moreover, normative data differs significantly between gender, age and activity, making data interpretation yet more challenging. Here we present a CRF assessment tool based on radar plots that provides a way to represent multivariate cardiorespiratory data from electrocardiographic (ECG) signals within its normative context. To that end, 5 parameters are extracted from raw ECG data using R-peak information: mean HR, SDNN, RMSSD, HRVI and the maximal oxygen uptake, VO2max. Our tool processes ECG data and produces a visualization of the data in a way that it is easy to compare between the performance of the user and normative data. This type of representation can assist both health professionals and non-expert users in the interpretation of CRF data.
Collapse
|
42
|
López-Mejías R, Genre F, Remuzgo-Martínez S, Pérez BS, Castañeda S, Llorca J, Ortego-Centeno N, Ubilla B, Mijares V, Pina T, Calvo-Río V, Palmou N, Miranda-Filloy JA, Parejo AN, Argila D, Sánchez-Pérez J, Rubio E, Luque ML, Blanco-Madrigal JM, Galíndez-Aguirregoikoa E, Ocejo-Vinyals JG, Martín J, Blanco R, González-Gay MA. Role of PTPN22 and CSK gene polymorphisms as predictors of susceptibility and clinical heterogeneity in patients with Henoch-Schönlein purpura (IgA vasculitis). Arthritis Res Ther 2015; 17:286. [PMID: 26458874 PMCID: PMC4603645 DOI: 10.1186/s13075-015-0796-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2015] [Accepted: 09/23/2015] [Indexed: 01/08/2023] Open
Abstract
Introduction To determine whether the PTPN22 (protein tyrosine phosphatase nonreceptor 22)/CSK (c-src tyrosine kinase) pathway is implicated in the susceptibility and clinical heterogeneity of Henoch-Schönlein purpura (HSP) in the largest series of Caucasian HSP patients ever assessed for genetic studies. Methods A set of 329 Spanish patients diagnosed with HSP fulfilling the American College of Rheumatology and the Michel et al. classification criteria and 515 sex and ethnically matched controls were recruited in this study. Two well-known CSK (CSK rs34933034 and CSK rs1378942) and two functional PTPN22 (PTPN22 rs2476601 (R620W) and PTPN22 rs33996649 (R263Q)) polymorphisms, previously associated with autoimmunity, were genotyped with TaqMan single nucleotide polymorphism (SNP) genotyping assays. Results No significant differences in the genotype and allele frequencies between HSP patients and controls were observed when the CSK rs34933034, CSK rs1378942, PTPN22 rs2476601 (R620W) and PTPN22 rs33996649 (R263Q) polymorphisms were analyzed independently. In keeping with this observation, no significant differences were found when we assessed these polymorphisms combined conforming haplotypes. In addition, there were no differences in the allele or genotype frequencies when HSP patients were stratified according the age at disease onset, sex, presence of arthralgia/arthritis, nephritis or gastrointestinal manifestations. Conclusions Our results do not support association between PTPN22/CSK and HSP. Electronic supplementary material The online version of this article (doi:10.1186/s13075-015-0796-x) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Raquel López-Mejías
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Avenida de Valdecilla, s/n, 39008, Santander, Spain.
| | - Fernanda Genre
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Avenida de Valdecilla, s/n, 39008, Santander, Spain.
| | - Sara Remuzgo-Martínez
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Avenida de Valdecilla, s/n, 39008, Santander, Spain.
| | - Belén Sevilla Pérez
- Department of Medicine, Hospital Universitario San Cecilio, Calle Dr. Oloriz, 16, 18012, Granada, Spain.
| | - Santos Castañeda
- Rheumatology Department, Hospital Universitario La Princesa, IIS-Princesa, Calle Diego de León, 62, 28006, Madrid, Spain.
| | - Javier Llorca
- Epidemiology and Computational Biology Department, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Avenida Cardenal Herrera Oria, s/n, 39011, Santander, Spain.
| | - Norberto Ortego-Centeno
- Department of Medicine, Hospital Universitario San Cecilio, Calle Dr. Oloriz, 16, 18012, Granada, Spain.
| | - Begoña Ubilla
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Avenida de Valdecilla, s/n, 39008, Santander, Spain.
| | - Verónica Mijares
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Avenida de Valdecilla, s/n, 39008, Santander, Spain.
| | - Trinitario Pina
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Avenida de Valdecilla, s/n, 39008, Santander, Spain.
| | - Vanesa Calvo-Río
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Avenida de Valdecilla, s/n, 39008, Santander, Spain.
| | - Natalia Palmou
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Avenida de Valdecilla, s/n, 39008, Santander, Spain.
| | - José A Miranda-Filloy
- Division of Rheumatology, Hospital Universitario Lucus Augusti, Calle Dr. Ochoa, s/n, 27004, Lugo, Spain.
| | - Antonio Navas Parejo
- Nephrology Department, Hospital Universitario San Cecilio, Calle Dr. Oloriz, 16, 18012, Granada, Spain.
| | - Diego Argila
- Dermatology Department, Hospital Universitario La Princesa, IIS-Princesa, Calle Diego de León, 62, 28006, Madrid, Spain.
| | - Javier Sánchez-Pérez
- Dermatology Department, Hospital Universitario La Princesa, IIS-Princesa, Calle Diego de León, 62, 28006, Madrid, Spain.
| | - Esteban Rubio
- Rheumatology Department, Hospital Universitario Virgen del Rocío, Avenida Manuel Siurot, s/n, 41013, Sevilla, Spain.
| | - Manuel León Luque
- Rheumatology Department, Hospital Universitario Virgen del Rocío, Avenida Manuel Siurot, s/n, 41013, Sevilla, Spain.
| | - Juan María Blanco-Madrigal
- Rheumatology Department, Hospital Universitario de Basurto, Avenida de Montevideo, 18, 48013, Bilbao, Spain.
| | - Eva Galíndez-Aguirregoikoa
- Rheumatology Department, Hospital Universitario de Basurto, Avenida de Montevideo, 18, 48013, Bilbao, Spain.
| | - J Gonzalo Ocejo-Vinyals
- Immunology Department, Hospital Universitario Marqués de Valdecilla, Avenida de Valdecilla, s/n, 39008, Santander, Spain.
| | - Javier Martín
- Institute of Parasitology and Biomedicine López-Neyra, CSIC, Avenida del Conocimiento, s/n, 18016, Granada, Spain.
| | - Ricardo Blanco
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Avenida de Valdecilla, s/n, 39008, Santander, Spain.
| | - Miguel A González-Gay
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Avenida de Valdecilla, s/n, 39008, Santander, Spain. .,Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, Parktown 2193, Johannesburg, South Africa.
| |
Collapse
|
43
|
Olveira G, Olveira C, Doña E, Palenque F, Porras N, Dorado A, Godoy A, Rubio E, Rojo G, Martín R. SUN-PP001: Oral Supplement Enriched in Hmb Combined with Pulmonary Rehabilitation Improves Body Composition, Bone Mineral Density, Muscle Strength and Health Related Quality of Life in Patient with Bronchiectasis (Prospective, Randomised Study). Clin Nutr 2015. [DOI: 10.1016/s0261-5614(15)30152-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
44
|
Lisbona M, Aguilera C, Leon P, Anaya M, Rubio E, Povedano J, Muñoz M. SAT0290 Prospective Observational Study of 5-Year Follow-Up of Distal Radius Fractures in a Trauma Center. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.6403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
45
|
Lόpez-Mejías R, Genre F, Sevilla Pérez B, Castañeda S, Ortego-Centeno N, Llorca J, Ubilla B, Remuzgo-Martínez S, Mijares V, Pina T, Calvo-Río V, Márquez A, Miranda-Filloy J, Navas Parejo A, Conde-Jaldόn M, Ortiz-Fernández L, Argila D, Aragües M, Rubio E, Leόn Luque M, Blanco-Madrigal J, Galíndez-Aguirregoikoa E, González Escribano F, Ocejo-Vinyals J, Martín J, Blanco R, González-Gay MΆ. THU0019 Association of HLA-B*41:02 with Henoch-Schönlein Purpura in Spanish Individuals Irrespective of the HLA-DRB1 Status. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4915] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
46
|
Rubio E, Lisbona M, Aguilera C, Muñoz A, Martinez R, Garrido N, Fernandez Alba M, Leon P, Hernandez Cruz B, Povedano J. SAT0146 Optimizing Treatment with Etanercept in Patients with Rheumatoid Arthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.6366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
47
|
Palmou-Fontana N, Loricera J, Blanco R, Hernández J, Castañeda S, Ortego N, Peirό E, Collado P, Melchor S, Mera A, Pérez-Pampín E, Rubio E, Calvo-Alén J, Aurrecoechea E, Rúa-Figueroa Í, Mínguez M, Herrero-Beaumont G, Bravo B, Rosas J, Narváez J, Calvo-Catalá J, Ariza R, Freire M, Lluch P, Mata C, Galíndez-Aguirregoikoa E, Blanco-Madrigal J, Sánchez-Andrade A, Salvatierra J, Calvo-Río V, González-Vela C, Pina T, González-Gay M. FRI0270 Tocilizumab Compared to Anti-TNFα Agents in Refractory Aortitis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
48
|
Cañete J, Pinto J, Gratacόs J, Queirό R, Ferrándiz C, Fonseca E, Montilla C, Torre-Alonso J, Puig L, Pérez Venegas J, Fernández Nebro A, Fernández E, Muñoz-Fernández S, Daudén E, González C, Roig D, Sánchez Carazo J, Zarco P, Erra A, Lόpez Estebaranz J, Rodríguez J, Moreno Ramírez D, de la Cueva P, Vanaclocha F, Herrera E, Castañeda S, Rubio E, Salvador G, Díaz-Torné C, Blanco R, Willisch Domínguez A, Mosquera J, Vela P, Tornero J, Sánchez-Fernández S, Corominas H, Ramírez J, Lόpez-Lasanta M, Tortosa R, Palau N, Alonso A, Julià A, Marsal S. OP0310 A Deletion at Adamts9-MAGI1 Locus is Associated with Psoriatic Arthritis Risk. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
49
|
Julià A, Pinto JA, Gratacós J, Queiró R, Ferrándiz C, Fonseca E, Montilla C, Torre-Alonso JC, Puig L, Pérez Venegas JJ, Fernández Nebro A, Fernández E, Muñoz-Fernández S, Daudén E, González C, Roig D, Sánchez Carazo JL, Zarco P, Erra A, López Estebaranz JL, Rodríguez J, Ramírez DM, de la Cueva P, Vanaclocha F, Herrera E, Castañeda S, Rubio E, Salvador G, Díaz-Torné C, Blanco R, Willisch Domínguez A, Mosquera JA, Vela P, Tornero J, Sánchez-Fernández S, Corominas H, Ramírez J, López-Lasanta M, Tortosa R, Palau N, Alonso A, García-Montero AC, Gelpí JL, Codó L, Day K, Absher D, Myers RM, Cañete JD, Marsal S. A deletion at ADAMTS9-MAGI1 locus is associated with psoriatic arthritis risk. Ann Rheum Dis 2015; 74:1875-81. [PMID: 25990289 DOI: 10.1136/annrheumdis-2014-207190] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2014] [Accepted: 04/23/2015] [Indexed: 12/11/2022]
Abstract
OBJECTIVE Copy number variants (CNVs) have been associated with the risk to develop multiple autoimmune diseases. Our objective was to identify CNVs associated with the risk to develop psoriatic arthritis (PsA) using a genome-wide analysis approach. METHODS A total of 835 patients with PsA and 1498 healthy controls were genotyped for CNVs using the Illumina HumanHap610 BeadChip genotyping platform. Genomic CNVs were characterised using CNstream analysis software and analysed for association using the χ(2) test. The most significant genomic CNV associations with PsA risk were independently tested in a validation sample of 1133 patients with PsA and 1831 healthy controls. In order to test for the specificity of the variants with PsA aetiology, we also analysed the association to a cohort of 822 patients with purely cutaneous psoriasis (PsC). RESULTS A total of 165 common CNVs were identified in the genome-wide analysis. We found a highly significant association of an intergenic deletion between ADAMTS9 and MAGI1 genes on chromosome 3p14.1 (p=0.00014). Using the independent patient and control cohort, we validated the association between ADAMTS9-MAGI1 deletion and PsA risk (p=0.032). Using next-generation sequencing, we characterised the 26 kb associated deletion. Finally, analysing the PsC cohort we found a lower frequency of the deletion compared with the PsA cohort (p=0.0088) and a similar frequency to that of healthy controls (p>0.3). CONCLUSIONS The present genome-wide scan for CNVs associated with PsA risk has identified a new deletion associated with disease risk and which is also differential from PsC risk.
Collapse
Affiliation(s)
- Antonio Julià
- Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain
| | - José Antonio Pinto
- Rheumatology Department, Complejo Hospitalario Juan Canalejo, A Coruña, Spain
| | - Jordi Gratacós
- Rheumatology Department, Hospital Parc Taulí, Sabadell, Barcelona, Spain
| | - Rubén Queiró
- Rheumatology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - Carlos Ferrándiz
- Dermatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
| | - Eduardo Fonseca
- Dermatology Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain
| | - Carlos Montilla
- Rheumatology Department, Hospital Virgen de la Vega, Salamanca, Spain
| | | | - Lluís Puig
- Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | | | - Antonio Fernández Nebro
- UGC Reumatología, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Málaga, Spain
| | - Emilia Fernández
- Department of Dermatology, Hospital Universitario de Salamanca, Salamanca, Spain
| | | | - Esteban Daudén
- Dermatology Department, Hospital Universitario La Princesa, Madrid, Spain
| | - Carlos González
- Rheumatology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain
| | - Daniel Roig
- Rheumatology Service, Hospital Moisès Broggi, Barcelona, Spain
| | | | - Pedro Zarco
- Rheumatology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - Alba Erra
- Rheumatology Department, Hospital Sant Rafael, Barcelona, Spain
| | | | - Jesús Rodríguez
- Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain
| | | | - Pablo de la Cueva
- Department of Dermatology, Hospital Universitario Infanta Leonor, Madrid, Spain
| | | | - Enrique Herrera
- Dermatology Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain
| | - Santos Castañeda
- Rheumatology Department, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain
| | - Esteban Rubio
- Rheumatology Department, Centro de Salud Virgen de los Reyes, Sevilla, Spain
| | - Georgina Salvador
- Rheumatology Department, Hospital Mútua de Terrassa, Terrassa, Spain
| | - César Díaz-Torné
- Rheumatology Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Ricardo Blanco
- Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | | | - José Antonio Mosquera
- Rheumatology Department, Complejo Hospitalario Hospital Provincial de Pontevedra, Pontevedra, Spain
| | - Paloma Vela
- Rheumatology Department, Hospital General Universitario de Alicante, Alicante, Spain
| | - Jesús Tornero
- Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain
| | | | | | - Julio Ramírez
- Rheumatology Department, Hospital Clínic de Barcelona and IDIBAPS, Barcelona, Spain
| | - María López-Lasanta
- Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain
| | - Raül Tortosa
- Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain
| | - Nuria Palau
- Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain
| | - Arnald Alonso
- Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain
| | | | - Josep Lluís Gelpí
- Life Sciences, Barcelona Supercomputing Centre, National Institute of Bioinformatics, Barcelona, Spain
| | - Laia Codó
- HudsonAlpha Institute for Biotechnology, Alabama, USA
| | - Kenneth Day
- HudsonAlpha Institute for Biotechnology, Alabama, USA
| | - Devin Absher
- HudsonAlpha Institute for Biotechnology, Alabama, USA
| | | | - Juan D Cañete
- Rheumatology Department, Hospital Clínic de Barcelona and IDIBAPS, Barcelona, Spain
| | - Sara Marsal
- Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain
| |
Collapse
|
50
|
Sahuquillo J, Poca MA, Rovira A, Raspall G, Chasampi A, Rubio E. A New Surgical Technique for the Treatment of Chiari I Malformation and Chiari I/Syringomyelia Complex: Preliminary Results in 10 Patients. Skull Base Surg 2015. [DOI: 10.1159/000429773] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|